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1. Summary 
Rationale 
At high altitude, individuals are at risk of suffering from symptoms of compromised immunity. 
This is associated with acute mountain sickness (AMS), high altitude pulmonary edema (HAPE), 
and high altitude cerebral edema (HACE) [1]. Exercise can provoke symptoms related to AMS, as 
well [2]. Studies implicate that hypoxia as well as exercise influence the human immune response 
by triggering angiogenesis and pro- and anti-inflammatory processes[3]. There is little data on 
the immune response on a molecular level, however. Therefore, the present study had following 
objective: 
 
Objective 
To explore blood cytokine and growth factor changes under the influence of hypobaric hypoxia 
alone and of physical exercise under both normobaric normoxia and hypobaric hypoxia. 
 
Methods 
The study used a non-randomized, non-blinded design with two parallel groups and an additional 
group. Participants conducted a resting trial (group 1, n=25) and/or exercise trial (group 2, n=18) 
both at sea level under normoxia (Bangor, UK; 69 m) and at high altitude after a 14-day-trek to 
5050 m under hypobaric hypoxia (Hidden Valley Base Camp, Dhaulagiri Circuit, Western 
Himalayan mountains, Nepal).  
Each trial included peripheral blood sampling either at rest (group 1) or before and 180 minutes 
after a 12-minute incremental step test (group 2).  
Additionally, blood was sampled from participants before and directly after a one-day climb from 
Hidden Valley Base Camp (5050 m) to Damphus Peak (6035 m) and back (group 3, n= 4).  
Blood was analyzed via Luminex xMAP Multiplexing Technology and radio immunoassay. Growth 
factors VEGF, EGF, FGF-2, TGF-β1, G-CSF, GM-CSF, IGF-1, IGFBP-1, and IGFBP-3 were measured. 
 
Results  
In group 1, hypobaric hypoxia alone caused an increase in VEGF (p = 0.039), EGF (p = 0.002), TGF-
β1 (p < 0.001), G-CSF (p = 0.029), and GM-CSF (p = 0.035). Furthermore, a decrease in IGF-1 (p < 
0.001) and IGFBP-3 (p < 0.001) was found. Markers were measured before and after each 
exercise trial (group 2 and 3). In group 2, EGF (p = 0.031) decreased after exercise under 
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normoxia at 69 m. In group 3, no changes were seen. Other cytokines and growth factors of 
groups 1, 2, and 3 were unchanged.  While hypobaric hypoxia is a potent stimulant of cytokines 
and growth factors, physical activity seems to have minor effects on these biomarkers. 
 
Conclusions  
The present study provides field data about changes in growth factors upon exposure to 
hypobaric hypoxia and physical exercise. It is known that cytokines and growth factors are 
influenced by hypoxia promoting angiogenesis, cell growth and repair, inflammation, and cancer 
[3-5]. Hypobaric hypoxia proved to be a potent trigger of significant changes in most cytokines 
and growth factors at rest. This may indicate the immunological response to counteract 
inflammation triggered by hypoxia and adapt to tissue hypoxia. Even though there is evidence 
that exercise amplifies the immunosuppression imposed by tissue hypoxia [6], this study shows 
that physical activity has only a minor impact on biomarkers both at sea level and high altitude.
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2. Introduction 
“Your attitude, not your aptitude, will determine your altitude” 
Hilary Hinton Ziglar 
 
Altitude is categorized into intermediate altitude [1500-2500 meters (m)], high altitude (2500-
3500 m), very high altitude (3500-5800 m), and extreme altitude (> 5800 m) [1]. About 50 million 
people of the American continent and 80 million people of the Asian continent permanently live 
above 2500 m [7]. Apart from permanent high altitude residents, people also travel to high 
altitude for business reasons or in order to pursue recreational activities.  
However, at altitude, individuals are at risk of experiencing potentially incapacitating symptoms 
which are associated with an increased incidence of acute mountain sickness (AMS) [8]. This 
apparent compromise of immunity limits work capacity and people are at risk to develop more 
severe clinical symptoms associated with diseases such as high altitude pulmonary edema 
(HAPE) and high altitude cerebral edema (HACE), ultimately putting them at risk of death. With 
increasing altitude, atmospheric pressure drops constantly, and inspired oxygen content is 
reduced. As a result, tissue hypoxia causes various changes in the autonomic nervous system and 
endocrine functions are evoked, which ultimately affects the human immune system.  
Apart from hypoxia, exercise has also a certain impact on the immune system. [2, 9, 10] Heavy or 
prolonged exercise can provoke symptoms related to AMS including symptoms of the common 
cold or upper respiratory tract infection symptoms. This apparent compromise of immunity [11] 
can occur at sea level in immunocompetent people. In subjects who experience chronic hypoxic 
sates, such as patients suffering from chronic lung or heart disease or people dwelling at high 
altitude, exercise can precipitate more severe deterioration of health. Therefore, the 
combination of high altitude hypobaric hypoxia and physical exercise represents a stressor which 
has a greater impact on immunity than that of either hypoxia or exercise alone [12-14].  
With increasing altitude, atmospheric pressure drops constantly, resulting in reduced inspired 
oxygen content. Consequently, tissue hypoxia poses stress to the homeostasis of the human 
body. Apart from hypoxia, exercise has also a certain impact on the immune system. [2, 9, 10]  It 
is suggested that exercise under hypoxic conditions provokes a more pronounced immunological 
response than exercise at normoxia. 
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The human immune system incorporates both innate and adaptive immune responses in order to 
provide host defense. The complex immunological processes are controlled and regulated at 
various sites and stages by a multitude of factors of which growth factors play a vital role.  
Therefore, the present investigation highlights potential links between the exposure to hypobaric 
hypoxia and changes in the growth factor milieu. Furthermore, growth factor levels after physical 
exercise both at sea level (69 m) and high altitude (5050 m) were studied. Insights are applicable 
to clinical conditions involving chronic respiratory and/or cardiovascular diseases. 
2.1. Hypoxia-Inducible Factor (HIF) 
Hypobaric [total ambient gas pressure less than 760 millimeters of mercury (mmHg)] hypoxia 
(inadequate oxygen tension at the cellular level) leads to either cell death or triggers a variety of 
survival mechanisms. Hypoxia-inducible factor (HIF) represents the main mediator of adaptation 
to hypoxia. [15-18]  
The HIF-pathway has been identified to regulate several hundred genes by direct or indirect 
modulation of gene expression [7]. Activation of HIF is shown in figure 1. 
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Figure 1 HIF-1α 
Under normoxic conditions, HIF prolyl hydroxylase (HPH) is activated by oxygen, subsequently hydroxylating 
HIF-1α. The von Hippel-Lindau (VHL)-complex recognizes hydroxylated HIF-1α and causes degradation of 
HIF-1α. Under hypoxic conditions, the lack of oxygen leaves HPH inactive. The VHL-complex does not detect 
unhydroxylated HIF-1α, which is stabilized and remains in its activated state. [19-21] 
HIF-1α Hypoxia Inducible Factor 1α, HPH HIF prolyl hydroxylase, VHL von Hippel-Lindau 
 
Active HIF-1α translocates to the nucleus and binds to hypoxia response elements of several 
target genes. Resulting transcription products include factors involved in angiogenesis [e.g., 
vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β1], cell growth 
[e.g., TGF-α, platelet-derived growth factor (PDGF], inflammatory response (e.g., cyclooxygenase-
1, IL-6), oxygen supply (e.g., erythropoietin), and metabolic processes such as adenosine 
triphosphate synthesis (e.g., glucose transporter-1). [19-21] 
2.2. Growth Factors 
Cytokines were first described in 1972 by Igal Gery and Byron Waksman as “lymphocyte 
activating factor[s]” [22]. Nowadays, cytokines are defined as soluble factors of variable size 
which are produced and released by many different cell types and exert manifold behavioral and 
HIF-1α
Normoxia
oxygen activates HPH
hydroxylated HIF is recognized by VHL-complex
protein degradation of HIF-1α
Inactive
Hypoxia
lack of oxygen leaves HPH inactive
unhydroxylated HIF-1α avoids detection by VHL-complex
HIF-1α is stabilized
Active
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functional effects on target cells. Once released, cytokines may act on another cell in a paracrine 
or endocrine way or on the releasing cell itself in an autocrine way. Furthermore, cytokines 
function as integral membrane proteins. [3] Growth factors and cytokines are often used 
synonymously which makes clear linguistic distinction difficult. In this work, however, growth 
factors are not used synonymously for, but represent a subgroup of cytokines. 
Growth factors comprise a complex family of biological factors that are produced by many 
different cell types in order to control cell growth, division, maturation, proliferation, migration, 
chemotactic attraction, and inhibition of mentioned actions, respectively [23]. After binding to 
their receptors, growth factors utilize specific multivariate signaling pathways which they share 
among each other. It has to be taken into account that once a growth factor has been secreted it 
has pleiotropic effects. That means that its actions are not limited to one type and effects are not 
limited to one specific cell type. [24, 25] Growth factors bind to receptors that are located either 
on only one specific type of cell or to receptors that are present on almost every cell. In the latter 
case, the cell type itself defines the property of the growth factor. Growth factors are not only 
pleiotropic but also fulfill their specific tasks in an overlapping manner. This highlights that the 
growth factor network as an immunological entity is based on a multiplication of function. For 
instance, each of the colony-stimulating factors [e.g., interleukin (IL)-3, granulocyte colony 
stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), 
macrophage colony stimulating factor (M-CSF)] is derived from a distinct gene and binds to its 
specific receptor, their biological properties, however, overlap markedly. At last, a remarkable 
feature of growth factor biology is the ambiguity in effects which may be both health promoting 
and damaging. [23] 
Growth factors are involved in the modulation of cell function, cell survival, and apoptosis [23], 
exert neuroprotective and neurotrophic effects on the central nervous system (CNS) [26],  act as 
angiogenic factors or inhibit angiogenesis, and regulate the expression of matrix 
metalloproteinases, and both fibrinolytic and fibrinogenic factors [4]. Growth factors promote 
cancer progression [27-31] and are used therapeutically to stimulate leucocyte production 
following chemotherapy or bone marrow transplantation [32]. Figure 2 provides an overview of 
characteristics of the growth factors investigated. 
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Figure 2 Growth factor functions  
Functional groups illustrate the effects of growth factors including involvement in cellular growth and repair, 
cancer, fibrosis, and inflammation. It highlights both their pleiotropy and multiplication of function [3, 4]. 
2.3. Growth Factor Groups 
The present study investigates growth factors of all major growth factor groups including vascular 
growth factors such as epidermal growth factor (EGF), VEGF, fibroblast growth factor 2 (FGF-2), 
and TGF-β1, hematological growth factors such as G-CSF and GM-CSF, and growth factors of the 
IGF-axis such as insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 2 
(IGFBP-2), and insulin-like growth factor binding protein 3 (IGFBP-3).  
2.3.1. Vascular Growth Factors 
Vascular growth factors have been identified to be both inducers (EGF, VEGF, FGF, and TGF-β) and 
inhibitors [soluble vascular endothelial growth factor receptor (sVEGFR)] of angiogenesis [33]. 
2.3.1.1. Epidermal Growth Factor (EGF) 
EGF is produced in both a membrane bound and soluble form by various cells including epithelial 
cells and fibroblasts [23, 34]. EGF is responsible for proliferation of epidermal, epithelial and 
endothelial cells. Its most important roles are promotion of wound healing processes which are 
brought about by its chemoattractant effects for fibroblasts and epithelial cells [35] and 
Growth
EGF
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FGF-2
TGF-β1
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G-CSF
IGF Axis
Repair
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VEGF
FGF-2
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induction of angiogenesis [23]. Uncontrolled signaling via the vascular endothelial growth factor 
receptor (EGFR) pathway such as overexpression of the EGF receptor has shown to promote 
tumor cell motility, adhesion, and metastasis [34, 36, 37]. Furthermore, EGF has been identified 
to play a role in tissue fibrosis [4]. 
Hypoxia potently stimulates the production of EGF which is implicated in pulmonary arterial 
hypertension by promoting proliferation, resistance to apoptosis, and migration of pulmonary 
vascular cells [20]. 
2.3.1.2. Vascular Endothelial Growth Factor (VEGF) 
The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, placental growth factor, and 
various alternative splicing products of VEGF-A [4, 38]. VEGF is expressed ubiquitously but is 
predominantly released in the lungs, cerebral choroid plexus, and in platelets [39, 40].  
VEGF expression is induced by various stimuli including growth factors (e.g., EGF, FGF-2 IGF-1, 
TGF-β1) and hypoxia [30, 38]. After binding to its receptors VEGF promotes chemotaxis and 
vascular permeability via VEGFR-1 [41] and cell proliferation and survival, mitogenic activities as 
well as vascular permeability via VEGFR-2 [42, 43]. VEGF is inactivated by soluble scavenger 
receptors (sVEGFR-1, sVEGFR-2) [30, 38]. Net effects of VEGF are cell survival and angiogenesis 
[41, 44].  However, VEGF has also been identified to be involved in pathophysiologic processes 
such as atherogenesis, restenosis [45], tissue edema [39], tumorgenesis [41], and metastatic 
spread of cancer [46, 47].  
Hypoxia potently stimulates the release of VEGF (via HIF-1α) which results in neovascularization 
and angiogenesis through enhanced capillarization and subsequent increase in oxygen delivery 
to peripheral tissues [30, 48]. Physical exercise is another stimulus changing VEGF concentrations 
under hypobaric hypoxia [48].  
2.3.1.3. Fibroblast Growth Factor 2 (FGF-2) 
FGF-2 is one of 22 currently known members of the FGF-family [49]. It is widely expressed in 
many tissues and cell types [50] and reaches high concentrations in brain tissue [51] and the 
pituitary gland [52, 53]. FGF-2 regulates the expression of its own receptors (up-regulation of 
FGFR1 and FGFR4 and down-regulation of FGFR2 and FGFR3) which has a net inhibitory effect on 
cell differentiation [54]. FGF signaling pathways are intertwined with various other growth factor 
pathways including the ones of IGF and TGF-β [55]. FGF-2 promotes cell growth [41], 
neurogenesis both in embryonic and adult CNS cells [56-58], morphogenesis, wound healing, 
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angiogenesis, pro-inflammatory actions [50], atherogenesis [45], lung and liver fibrosis [3], and 
tumor growth and progression [58-60]. Under hypoxic conditions, FGF mediates the proliferation 
of vascular cells [20].  
2.3.1.4. Transforming Growth Factor β 1 (TGF-β1) 
The TGF-β family includes three isoforms (TGF-β1, -2, and -3). TGF-β1 is the most widely 
expressed isoform and is involved in the control of multiple biological processes including cell 
growth and differentiation, homeostasis, and modulation of immunological processes. 
Respective receptors include TGF-β receptor 1 to 3 (TGF-βR-1, -2, -3).[41, 61, 62] TGF-β1 is 
released from endothelial cells, epithelial cells, fibroblasts, regulatory T-cells, and hepatocytes 
[62, 63] and exerts both growth-promoting [4] and -inhibitory [41] effects on target cells. It 
regulates the cell cycle by freezing the cell cycle at the G1 stage in order to halt proliferation, 
induce differentiation, or promote apoptosis [64]. In analogy, TGF-β1 both stimulates and inhibits 
immunological processes [62]. It is a potent stimulator of chemotaxis demonstrated by migration 
of monocytes, lymphocytes, neutrophils, and fibroblasts [4, 65] but also inhibits the activation of 
lymphocytes and monocyte derived phagocytes [66, 67]. TGF-β1 is a crucial factor in 
angiogenesis and has both growth-promoting and -inhibitory effects on angiogenesis [4, 68]. 
Interaction with other growth factors is demonstrated by the up-regulation of VEGF by TGF-β1 
along with a concomitant down-regulation of VEGFR-2 which impedes VEGF-mediated effects. 
The net effect of TGF-β1 is therefore anti-proliferative. [41, 69, 70] 
Uncontrolled TGF-β1 signaling is implicated in pathologies such as inflammation, autoimmune 
disorders [71, 72], fibrosis [4], and cataracts [71, 72]. Extensive studies have been undertaken 
with respect to oncogenesis, where TGF-β both serves as a proto-oncogene and a tumor 
suppressor [62]. TGF-β is often co-expressed with VEGF in cancer [41]. TGF-β1 is not only 
involved in homeostasis in healthy lung tissue by regulating pulmonary cell proliferation and 
modulating the immune response, but also involved in asthma, COPD, lung fibrosis, and lung 
cancer [73-75]. 
Hypoxia induces TGF-β1-mediated angiogenesis causing proliferation and migration of vascular 
endothelial cells [62, 68, 76]. Furthermore, physical exercise induces TGF-β-mediated tissue 
repair [77, 78].  
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2.3.2. Hematological Growth Factors 
2.3.2.1. Granulocyte-Colony Stimulating Factor (G-CSF) 
While G-CSF is produced by all tissues in the body, the most relevant sites of production include 
macrophages, endothelial cells, fibroblasts, and related mesenchymal cells. The G-CSF receptor is 
expressed by all neutrophils and their precursors in the bone marrow, by neurons in the brain 
and spinal cord, endothelial cells, placental cells, activated T-lymphocytes, and many non-
hematopoietic tumor cell lines [79]. G-CSF induces proliferation and promotes chemotaxis in all 
cells of the granulocyte lineage in bone marrow cells and activates their immunological functions 
such as superoxide production, phagocytosis, and bactericidal killing [80]. Apart from effects on 
the hematopoietic system, G-CSF acts also as a promoter of neurogenesis [81]. G-CSF both has 
pro-inflammatory (modulation of T-lymphocyte development and function) [79] and anti-
inflammatory (triggering the release of IL-4 and IL-6) [82-84]effects. G-CSF plays a role in 
rheumatoid arthritis[79] and cancer [85, 86]. 
Under hypoxic conditions, G-CSF has been shown to be involved in cell-survival and protection 
from ischemic injury in brain [26]. Additionally, physical exercise, exemplified by an Ironman 
triathlon race, causes an up-regulation of G-CSF [87]. 
2.3.2.2. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) 
GM-CSF is secreted by macrophages, T-lymphocytes, mast cells, NK cells, endothelial cells, 
fibroblasts [88], chondrocytes, and smooth muscle cells [89] and regulates various processes of 
both innate and adaptive immunity including  proliferation, differentiation, activation, and 
survival of hematopoietic stem cells including myeloid and lymphoid cells [90]. Moreover, it has 
been shown that in response to a stimulatory signal (e.g., lipopolysaccharide, cytokines, and 
antigen) GM-CSF triggers the production of major inflammatory cytokines such as IL-1 and tumor 
necrosis factor (TNF)-α and growth factors including G-CSF and macrophage colony-stimulating 
factor [91]. 
On the one hand, anomalous expression of GM-CSF production or aberrant receptor function are 
implicated in pathologies including chronic myeloid leukemia, myeloproliferative diseases, tissue 
fibrosis (via induction of TGF-β1 release) [4], asthma, rheumatoid arthritis [89], juvenile 
myelomonocytic leukemia, chronic myelomonocytic leukemia, and alveolar proteinosis, on the 
other hand, GM-CSF represents a therapeutic approach in Crohn´s disease through its induction 
of immunological processes aimed against cancer cells and promotion of innate immunity [90]. 
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2.3.3. The Insulin-Like Growth Factor Axis 
Insulin like growth factors (IGFs) comprise a family which is structurally very closely related to 
insulin. The IGF axis consists of IGF-1 and IGF-2, the respective receptors IGF-1R and IGF-2R, IGF 
binding proteins (IGFBPs)-1 to 10, and IGFBP proteases. [92] The majority of the IGFs are bound 
to IGFBPs [93, 94] (75% are bound to IGFBP-3 [95]). IGFBPs have a higher affinity to IGF than IGF 
receptors to IGF [96]. IGFBPs regulate either positively or negatively IGF-mediated effects by 
releasing or binding them [93, 94]. IGFBPs transport IGFs, regulate their efflux from the 
circulation, prolong their half-lives, and modify their metabolic clearance [97]. On a local level, 
IGFBPs exert paracrine and autocrine control resulting in modulation of local IGF effects, altered 
local growth and metabolism, and activation of various signaling pathways [98]. IGFBP proteases 
lower the affinity with which IGFBPs bind IGFs [96]. Both the production of IGFs and IGFBPs is 
influenced by the growth hormone (GH) [98].  
IGF-1 exists in two isoforms (IGF-1Ea and IGF-1Ec). IGF-1Ea is produced mainly in the liver upon 
GH stimulation and acts systemically in an endocrine fashion. IGF-1Ec is produced by various 
extrahepatic cell types and acts locally as an autocrine/paracrine growth factor under the control 
of different hormones. Systemic IGF-1Ea has a longer half-life than local IGF-1Ec due to 
glycosylation which protects it from proteolytic degradation. [99] 
Unbound (bioactive) IGF-1 is positively correlated with total IGF-1 levels and IGFBP-3 levels, while 
it is negatively correlated with levels of IGFBP-1 and IGFBP-2. Insulin reduces levels of bioactive 
IGF-1 which presumably is due to simultaneous insulin-induced increases of IGFBP-2 which in 
turn binds and inactivates IGF-1. Reduced levels of unbound (bioactive) IGF-1 trigger the up-
regulation of GH via a negative feedback loop. [100]  
IGFBP-1 production is dependent on [96] and negatively correlated with insulin [101]. 
IGF-1 is a vital factor of pre- and post-natal body growth and is especially important in growth of 
bone and muscle [93, 94, 99]. IGF-1 is involved in pathologies such as growth deficiency [94], 
osteoporosis [99], oncogenesis [6], atherosclerosis [100], and muscle mass wasting [99] which is 
a feature of malnutrition, critical illness and sepsis [93]. 
IGFBPs are momentous adjuncts, because they extend IGF-1 half-life from estimated 10 minutes 
to 15 hours when bound to IGF-1 [97]. Of the family of high-affinity IGF binding proteins (IGFBP-1 
to 10) [92] regulatory effects of IGFBP-1 and IGFBP-3 on IGF-1 are highlighted in this work.  
While both IGFBP-1 and IGFBP-3 is mainly produced in the liver [94, 96], the majority of IGFs (75-
80%) are bound to IGFBP-3 and only small quantities of them are bound by IGFBP-1 [95]. 
IGFBPs regulate the half-life of IGF-1 and its interaction with the IGF-1 receptor.  
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The following features of IGFBP-3 are exemplary for IGFBPs. Growth inhibitory effects are 
brought about by IGFBP-3 binding IGF-1 and thus scavenging it from the IGF-1 receptor. The 
IGFBP-3-IGF-1-complex is contained to the vascular compartment and even is able to guide IGF-1 
to specific tissues and cell types. Growth stimulation, on the other hand, is brought about by 
liberating IGF-1 from IGFBP-3 through either proteolysis of IGFBP-3 or binding of IGFBP-3 to 
extracellular matrix proteins. [93, 98] Furthermore, actions not involving IGFs have been 
described for most IGFBPs and include binding to integrins or cell-membrane receptors [99, 102, 
103]. While IGFBP-1 is involved in vasodilation by activation of nitric oxide (NO) production [103], 
IGFBP-3 induces apoptosis via protein 53 (p53) [6] and is involved in wound healing [98]. 
Additionally, IGFBP-3 is involved in cancer as a tumor-suppressor both in a direct and indirect (via 
TGF-β) way [98]. Furthermore, IGFBP-3 inhibits VEGF-mediated angiogenesis [104]. 
Physical exercise stimulates the GH-IGF-1-axis, which has anabolic effects [105] and is involved in 
tissue remodeling upon muscle damage [77, 78]. 
Various studies provide evidence for a hypoxia-induced up-regulation of IGFBP-3 [98, 106]. 
Hypoxia indirectly up-regulates IGFBP-1 levels which represents a mechanism in atherosclerosis 
[107]. Studies imply that hypoxia causes fetal growth restriction. In pregnant women, IGFBP-1 
levels were significantly higher at high altitude than at sea level. It is assumed that placental 
hypoxia caused by hypobaric hypoxia at high altitude triggers a HIF-1-mediated up-regulation of 
IGFBP-1 in order to limit IGF-mediated fetal growth. This IGFBP-1-mediated growth restriction 
attenuates fetoplacental hypoxia and ultimately prevents fetal death. [108, 109] Intrauterine 
growth restriction may predispose to preterm birth which in turn is associated with low birth 
weight and low growth velocity in childhood. Eventually, perinatal growth restriction may be a 
predisposing factor for disorders such as cardiovascular disease or diabetes. [110] Another study 
reported that transcription levels of IGF-1 or IGFBP-3 in vertebrate embryonic cells were 
unchanged by hypoxia, however [101]. 
 
Having presented the most poignant facts about growth factor physiology, the present study 
aims to highlight less investigated issues. Therefore, following hypotheses arose.
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3. Hypotheses 
1. Does hypobaric hypoxia at high altitude (5050 m) induce changes in growth factor levels 
when compared to sea level (69 m)?  
2. Does physical exercise induce changes in growth factor levels at sea level (69 m) and/or high 
altitude (5050 m)? 
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4. Materials and Methods 
All samples and entailing data sets have been acquired during both data collection sessions in 
Bangor [United Kingdom (UK)] in June 2008 and an international medical expedition (Hidden Valley 
Expedition 2008) in the Western Himalayan Mountains (Dhaulagiri Circuit, Nepal) in September 
2008. Both were organized by Medical Expeditions. Data presented in this study originates from a 
pool shared by the cross-over study of Jennifer Landerer presenting complementary findings with 
respect to cytokine interaction during a high altitude (5050 m) sojourn. 
4.1. Materials 
4.1.1. Equipment 
Sterican® 20-Gauge needle (B. Braun Melsungen AG, Melsungen, Deutschland), EDTA VacutainerTM 
(BD, Franklin Lakes, New Jersey, USA), Heparin VacutainerTM (BD, Franklin Lakes, New Jersey, USA), 
Eppendorf tubes of 1.5 ml (Eppendorf AG, Hamburg, Germany), pipette (Genex Β) (Genex 
Laboratories, Torquay, UK), centrifuge (Eppendorf MiniSpin) (Eppendorf AG, Hamburg, Germany), 
pulse oximeter (Nonin Onyx 9500) (Nonin Medical Inc., Plymouth, Minnesota, USA), barometric 
pressure wrist watch  (Suunto X3HR) (Suunto Oy, Vantaa, Finland), ratings of perceived exertion 
(Borg, 1982)  and mood (Feeling scale -5/+5: Hardy and Rejeski, 1989), SigmaStat and SigmaPlot 
(Systat Software, Inc., San José, California, USA), heart rate monitor (Polar S120) (Polar, Kempele, 
Finland), Eppendorf Thermomixer comfort (Eppendorf AG, Hamburg, Germany), Luminex 100 
(Luminex Corporation, Austin, Texas, USA), hemoglobin-photometer (HemoCue Plasma/Low Hb 
Photometer, Sweden/UK), centrifuge (HaematoSpin 1400, Hawksley, UK), hematocrit reader (Tube 
reader, Hawksley, UK), new Neubauer chamber. 
4.1.2. Chemicals 
20-plex Premixed Human Cytokine Milliplex Map Panel Immunoassay (Cat. # SPRPMX21) including 
EGF, FGF-2, G-CSF, GM-CSF, VEGF and TGF-β1 Single Plex Kit (Cat. # TGFB-64K-01), Human Cytokine / 
Chemokine Standard, Human Cytokine Quality Controls 1 and 2, Serum Matrix, Assay Buffer, Wash 
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Buffer, Human Cytokine Detection Antibodies, Streptavidin-Phycoerythrin (Merck Millipore, Billerica, 
Massachusetts, USA), and Sheath Fluid (Luminex). 
4.2. Methods 
4.2.1. Study Population 
The study formed one of a series completed on the “Hidden Valley Expedition 2008” to Nepal. The 
study was approved by both the Coventry Ethics Committee and the Nepal Health Research Council, 
and all participants provided written informed consent. 
All 26 subjects of the study were healthy moderately active expedition members. The differing total 
numbers of participants in the 3 groups are due to the fact that individual subjects voluntarily took 
part in either all groups or two or only one and due to the fact that some subjects only took part at 
sea level (69 m) but not at high altitude (5050 m) for differing reasons (e.g., exhaustion, illness). That 
is why for instance in group 2 as many as 10 subjects took part at sea level (69 m), but only 8 
subjects at high altitude (5050 m). For further demographic data, see table 1.  
 
Table 1 Demographic data 
The table shows demographic data of expedition members who participated in the present study. Values are 
expressed as mean (standard deviation), except for gender distribution (absolute numbers).  
M male, F female, BMI body mass index [body weight in kilograms per square meters (kg x m2)] 
  Whole Group Group 1  Resting Group 2  Exercise Group 3 Damphus Peak Sex, M : F 16 : 10 15 : 10 5 : 3 4 
Age, years 33.1 (± 11.74) 32.8 (± 11.33) 32.8 (± 8.44) 26.0 (± 3.91) 
BMI, kg x m2 23.33 (± 12.90) 22.48 (± 13.57) 27.12 (± 14.43) 14.25 (± 11.78)  
4.2.2. Study Design 
The study shows a non-randomized, non-blinded design with two parallel groups and an additional 
third group. For the explanation for the differing total numbers of participants in the 3 groups see 
“4.2.1. Study Population”. Further detail is shown in table 2.  
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Table 2 Number of participants in the 3 groups studied 
The table shows the distribution of participants and the strength of the different groups both at sea level (69 m) and 
high altitude (5050 m). Values are expressed as absolute numbers of participants. 
  Whole Group Group 1  Resting Group 2  Exercise Group 3 Damphus Peak Total 26 25 10 4 
Sea level (69 m) 25 25 10 - 
High altitude (5050 m) 18 18 8 4  
Group 1 members represent the reference group at rest. This group was comprised of 25 
participants at sea level (69 m) and 18 at high altitude (5050 m).  
Group 2 members underwent an incremental exercise test and totaled to 10 at sea level (69 m) and 
8 at high altitude (5050 m).  
In addition, a third group of 4 participants underwent a one-day climb from Hidden Valley Base 
Camp (5050 m) to Damphus Peak (6035 m) and descending back to Hidden Valley Base Camp.  
The difference in altitude from ascent to Damphus Peak (6035 m) to descent to Base Camp (5050 m) 
totaled to 1970 meters.  
In accordance with ethical approval from Coventry University Ethics Committee, participants gave 
their written informed consent to participate in the study in order to verify that they were fully 
informed of the study’s requirement and had been notified of and understood the possible risks. In 
addition, participants completed a health screen questionnaire prior to conducting each of the two 
trials. 
It has to be taken into account that subjects may or may not have participated in other double-
blinded studies of which one applied carbohydrate supplementation and the other inhaled Iloprost.  
4.2.3. Inclusion and Exclusion Criteria 
Inclusion criteria were normal hemoglobin and hematocrit values (quantified prior to commencing 
the expedition). Subjects were also asked to refrain from consuming food for at least 2-3 hours prior 
to exercise. All subjects were non-smokers over the age of 18 years.  
Exclusion criteria were a history of cardiovascular, respiratory, nervous, renal, liver, skeletal/muscular 
and metabolic disease. Furthermore, none of the participants suffered from immunosuppression 
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from HIV, was on any regular medication, or had suffered recently an allergic reaction. Other medical 
conditions were well controlled and individuals were free of symptoms at the time of the expedition’s 
departure.  
4.2.4. Data Collection Protocol 
The study consisted of two trials of data collection. The first trial was conducted at Bangor 
University, UK in July/August 2008 [69 m, barometric oxygen pressure (p02) 760 mmHg] and the 
second trial took place at Hidden Valley Base Camp, Nepal in October 2008 (5050 m, p02 550 
mmHg). 
4.2.5. Expedition Itinerary 
The main route of ascent corresponded to the Dhaulagiri Circuit in the Western part of the Nepalese 
Himalayas. On the way to Hidden Valley Base Camp at 5050 m expedition members were exposed to 
various climatic conditions such as hot weather zones, humid subtropical climate, monsoon rain, and 
finally a permafrost zone above 3000 m. Expedition members were divided into four trekking groups, 
each of which departed on a different day. While figure 3 shows the complete expedition itinerary, 
figure 4 shows the corresponding altitude profile. For starting and end points of the expedition 
itinerary see table 7 in the appendix.  
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Figure 3 Expedition itinerary  
The expedition itinerary is outlined in blue and surrounding peaks in red. Locations titled do not correspond to starting and end points of each expedition day. [111] 
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Figure 4 Altitude profile 
The expedition in the Nepalese Himalayas started at Beni (826 m), went via the Dhaulagiri Circuit for 14 days in 
order to arrive at Hidden Valley Base Camp (5050 m). After 6 days of research the expedition went on and ended in 
Jomsom (2720 m).   
4.2.6. Collection of Blood Samples 
4.2.6.1. Set-up 
Baseline resting blood samples were taken from a population of 25 participants (10 women, 15 men) 
in Bangor (UK, 69 m) and of 18 participants (7 women, 11 men) in Hidden Valley Base Camp (Nepal, 
5050 m) who were all overnight fasted (minimum 8 hours fast). Participants remained in a seated 
position for 15 minutes prior to venipuncture from an antecubital vein by means of a 20-Gauge 
needle. A total amount of 6 ml blood was distributed into 1 EDTA and 1 Heparin VacutainerTM of 3 ml 
each. 
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Subjects who underwent an incremental step test were comprised of a population of 8 participants 
in Bangor (69 m) and 8 participants in Hidden Valley Base Camp (5050 m). Participants were fasted at 
least for 2-3 hours prior to the first and remained fasted until the last phlebotomy. 
After the first phlebotomy an incremental step test was undertaken. Each participant stepped on and 
off a 25 centimeter metal step over a period of twelve minutes in total subdivided into three 
intervals of four minutes each. An acoustic beeping signal indicated the step-frequency which was 
for the first interval 13 steps per minute, for the second 26 steps per minute, and with initiation of 
the third interval the beeping signal was turned off and the subject was asked to apply a step-
frequency as high as possible. One entire stepping cycle consisted of putting one foot on the step 
with the first beep, followed by the second foot with the second beep, so that the participant was 
standing with both feet on the step. With beep three and four, the feet were brought down in the 
same fashion one by one. Every minute the leading foot was changed in order to prevent exhaustion 
of one particular lower limb. Immediately prior to and during exercise heart rate (Polar S120, Polar, 
Kempele, Finland), ratings of perceived exertion and mood (Feeling scale -5/+5) were recorded at 
minute intervals. Four more blood samples were taken directly after, 15 min, 90 min, and 180 min 
after cessation of exercise. A total of 30 ml of blood was collected per participant. 
A supplementary third group was formed by four subjects (all male) who undertook a one-day climb 
from Hidden Valley Base Camp (5050 m) to Damphus Peak (6035 m). After an overnight fast, blood 
samples were taken from participants at 03:30 a.m. (local time) prior to ascent and directly after 
return from the Damphus Peak summit. During their climb participants did not remain fasted. 
Meters covered on ascent and descent totaled to 1970. Duration of ascent and descent averaged to 
12 hours (from 03:30 a.m. until 3:30 p.m.).  
4.2.6.2. Processing of Blood Samples 
Immediately after venipuncture the utilized EDTA VacutainerTM was aliquoted into 2 Eppendorf tubes 
of 1.5 ml each by means of a pipette (Genex B). Same procedure was applied to the utilized Heparin 
VacutainerTM. Within 30 minutes after venipuncture Eppendorf tubes were spun in a centrifuge 
(Eppendorf MiniSpin) for 10 minutes at sea level (69 m) and for 5 minutes at high altitude (5050 m) 
at a relative centrifugal force of 12,000. Afterwards, plasma from the 2 EDTA and 2 Heparin aliquots 
was distributed to 6 and 2 Eppendorf tubes of 0.5ml each, respectively.  
Materials and Methods 
28 
4.2.6.3. Storage and Transport of Blood Samples 
After processing, blood samples were sealed in plastic bags and kept at -26° Celsius (C) in a freezer. 
At Hidden Valley Base Camp (Nepal, 5050 m), the portable freezer was insulated with a styrofoam 
case and cooled via a gas cartridge on the day of descent. Transportation of the freezer by foot to 
the nearest town with electrical supply for cooling took 8 hours. During transportation a remote 
sensor in the freezer allowed for real time temperature readings and re-cooling via a gas cartridge 
provided stable temperatures of at least -10° C or below. Subsequently, samples were transported by 
plane from Nepal to the UK, where samples from the first trial were added and finally sent via air 
mail to the laboratory in Homburg (Germany). 
4.2.7. Immunoassay 
In order to analyze specimen Luminex xMAP Multiplexing Technology was employed. Following 
growth factors were measured simultaneously: VEGF, EGF, FGF-2, TGF-β1, G-CSF, GM-CSF.  
In cooperation with the University of Gießen, courtesy of the laboratory of Prof. Dr. Blum, IGF-1, 
IGFBP-1, IGFBP-3 were analyzed by means of a radio immunoassay (RIA) [112]. In RIA, the analyte 
(antigen) is measured by coupling antibodies specific for the antigen to a test tube. In a second step, 
the patient serum containing the antigen is added and antibodies bind the antigen. Non-bound 
antigen is subsequently removed by washing. In a further step, radiolabeled antibodies specific to 
the antigen are added. After washing, radioactivity is determined. [113, 114] 
4.2.7.1. Luminex xMAP Multiplexing Technology 
Luminex allows simultaneous analysis of exact quantities of a large number of small-volume 
samples. It is a highly specific, sensitive, and reliable assay. [115, 116]  
Luminex is based on flow cytometry and employs as the key principle the fluorescent color coding of 
microspheres (polystyrene particles) allowing their identification and precise correlation with their 
respective population through optical analysis. Through combination of red and infrared fluorescent 
dyes 100 (102) different fluorescent color tones are created. One unique bead class is made up by 
one microsphere dyed with one of the 100 different fluorescent color tones and its specific capture 
antibody. Specific reaction partners (analytes) bind to the microsphere´s capture antibody. The 
resulting complex (bead + capture antibody + analyte) is recognized by a detection antibody and 
subsequently labeled with so-called reporter molecules. The median fluorescence intensity of the 
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reporter molecule is then used to quantify the amount of analyte bound to the bead. In this manner, 
a single sample of a volume as small as 25 μl can be incubated with up to 100 different bead classes 
at the same time on a 96-well-microtiter plate.   
After the binding reaction is completed, microspheres are suctioned from the microtiter plate. While 
two lasers are directed at the particle stream, mirrors direct fluorescence discriminator signals 
emitted from microspheres and detection signals emitted from reporter molecules to detectors. 
Figure 5 shows the set-up of the bead (microsphere) technology. Photodiodes classify the 
microspheres and detect side scatter signals of the particles, which allows determination of the 
particle size and exclusion of fluorescent contaminants or microsphere aggregates (e.g., doublets) 
from the results, respectively. A special laser excites the fluorescent dye of the reporter molecules 
and the intensity of the emitted light allows for quantification of the analyte bound to a particular 
microsphere. Finally, optical signals are translated into digital signals. With the Luminex analysis 
system, up to 20,000 events per second can be amplified, processed and recorded. [117]  
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Figure 5 The bead (microsphere) technology of Luminex 
Luminex employs as the key principle the fluorescent color coding of microspheres (polystyrene particles) allowing 
their identification and precise correlation with their respective population through optical analysis. One unique bead 
class is made up by one microsphere dyed with one of the 100 different fluorescent color tones and its specific 
capture antibody. Specific reaction partners (analytes) bind to the microsphere´s capture antibody. The resulting 
complex (bead + capture antibody + analyte) is recognized by a detection antibody and subsequently labeled with a 
so-called reporter molecule. While two lasers are directed at the particle stream, mirrors direct fluorescence 
discriminator signals emitted from microspheres and detection signals emitted from reporter molecules to detectors. 
Photodiodes classify the microspheres and detect side scatter signals of the particles. The median fluorescence 
intensity of the reporter molecule is then used to quantify the amount of analyte bound to the bead. Optical signals 
are finally translated into digital signals. [117] 
4.2.7.2. Assay 
Before analysis, samples were prepared as recommended by the manufacturer’s instructions (see 
figure 6). Premixed antibody-immobilized beads were sonicated for 30 seconds and vortexed for 1 
minute. Quality controls 1 and 2 were generated by adding 250 μl deionized water, mixing and 
vortexing the vials (rest before use: 5-10 min) and pipetting them into test tubes. At room 
temperature 30 ml of wash buffer were diluted with 270 ml deionized water. 1.0 ml of deionized 
water was mixed into the bottle containing lyophilized Serum Matrix (rest before use: 10 min). 
Adding 250 μl deionized water resulted in human cytokine standard (10,000 pg/ml). Working 
standards were generated by serial dilutions of the standard dilution (10,000 pg/ml). Five test tubes 
were filled with 200 μl of Assay Buffer (0 pg/ml). 50 μl of the 10,000 pg/ml standard was added to 
tube 1 (= 2000 pg/ml). 50 μl of tube 1 was added to tube 2 (= 400 pg/ml). 50 μl of tube 2 was added 
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to tube 3 (= 80 pg/ml). 50 μl of tube 3 was added to tube 4 (= 16 pg/ml). 50 μl of tube 4 was added 
to tube 5 (= 3.2 pg/ml).  
 
 
Figure 6 Assay preparation 
Before analysis, samples were prepared as recommended by the manufacturer’s instructions. 1.0 ml of deionized 
water was mixed into the bottle containing lyophilized Serum Matrix and 250 μl deionized water was added which 
resulted in the human cytokine standard (10,000 pg/ml). Working standards were generated by serial dilutions of the 
standard dilution (10,000 pg/ml). Five test tubes were filled with 200 μl of Assay Buffer (0 pg/ml). 50 μl of the 
10,000 pg/ml standard was added to tube 1 (= 2000 pg/ml). 50 μl of tube 1 was added to tube 2 (= 400 pg/ml). 50 μl 
of tube 2 was added to tube 3 (= 80 pg/ml). 50 μl of tube 3 was added to tube 4 (= 16 pg/ml). 50 μl of tube 4 was 
added to tube 5 (= 3.2 pg/ml). [118] 
pg pictogram, ml milliliter, µl microliter 
 
After adding 200 μl of Assay Buffer into each of the 96 wells the microtiter plate was sealed and 
mixed on a plate shaker (Eppendorf Thermomixer comfort) at 500 revolutions per minute (rpm) for 
10 minutes at room temperature (20-25° C). Assay Buffer was then removed and 25 μl of each 
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Standard and Quality Control solution were pipetted into the respective wells. Assay Buffer was used 
for the 0 pg/ml standard (background). Each sample well was filled with 25 μl of Assay Buffer and 25 
μl of Serum Matrix solution was added to each of the Background, Standards, and Quality Control 
wells. Eventually, 25 μl of each sample was pipetted into the appropriate wells. The bottle containing 
the premixed beads was vortexed and 25 μl of the bead mix were added to each well.  
After incubation (60 min at 20-25° C) on the plate shaker the fluid phase was removed from the 
microtiter plate and each well was washed 2 times with 200 μl of Wash Buffer.  
Before a second incubation process (30 min at 20-25° C) began, 25 μl of Detection Antibodies were 
added to each well. After pipetting 25 μl of Streptavidin R-Phycoerythrin into each well, a third 
incubation period (30 min at 20-25° C) on the plate shaker began. All fluid was removed from the 
microtiter plate and each well was washed 2 times with 200 μl of Wash Buffer. Each well was then 
filled with 150 μl of Sheath Fluid, the plate was put on a plate shaker for 5 minutes, and ultimately 
inserted into the Luminex 100™ IS. The Median Fluorescent Intensity (MFI) data was saved and 
growth factor concentrations in samples were calculated.  
 
TGF-β1  
The assay for TGF-β1 equals to the assay mentioned above. In the following chapter only alterations 
from the protocol are portrayed:  
Quality controls 1 and 2 were reconstituted with 250 μl Assay Buffer and mixed and vortexed (rest 
before use: 5-10 min). 
Wash Buffer was brought to room temperature and mixed until salts were brought into solution. 30 
ml of Wash Buffer was diluted with 270 ml deionized water.  
1.0 ml of deionized water and 4.0 ml of Assay Buffer were added to the bottle containing lyophilized 
Serum Matrix (rest before use: 10 min) and mixed. Of this mixture 0.5 ml were added to 0.5 ml Assay 
Buffer in order to get the final dilution of 1:10 of the working Serum Matrix used for Standards and 
Controls.  
Samples were centrifuged and 1 part of sample was diluted with 4 parts of Sample Diluent (e.g., 20 
μl sample and 80 μl Cat. # LTGF-SD) (dilution 1:5). To each 25 μl of the 1:5 diluted samples 2.0 μl of 
1.0 N HCl was added in order to have the pH drop below 3.0. After mixing, acidified samples were 
shaken at room temperature for 15 min and finally diluted with Assay Buffer (Cat. # L-MAB) in a 1:6 
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ratio in order to get a final sample dilution of 1:30. These diluted samples were then immediately 
added to the sample wells.  
For the preparation of TGF-β1 standard 250 μl Assay Buffer was added (= 10,000 pg/ml), mixed, and 
vortexed for 10 seconds (rest before use: 5-10 min). 
Working standards of 2500, 625, 156, 39, and 9.8 pg/ml were generated by adding 150 μl of Assay 
Buffer to five tubes and carrying out serial dilutions as described above.  
After preparation of the wells as mentioned earlier, the plate was prepared for incubation on a plate 
shaker at 20-25° C. After two incubation periods (2 h and 1 h, respectively) all fluid contents were 
removed, each well was filled with 100 μl of Sheath Fluid, and the plate was put on the plate shaker 
for another 5 minutes. Final steps were equal to the ones of the protocol mentioned above.  
For well maps of both assays see figures 10 and 11 in the appendix.  
4.2.7.3. Software 
Data was analyzed using Luminex IS 2.3 and both MFI and calculated concentration values were 
reported for each analyte. 
4.2.8. Statistical Method 
Statistical analysis was performed using SigmaStat 3.1 (Systat Software, Point Richmond, CA, USA). 
Differences between sea level (69 m) and high altitude (5050 m) values as well as between pre-
exercise and post-exercise values were analyzed using the Wilcoxon test. Values of p < 0.05 were 
considered statistically significant. Results are presented as median (Min; Max). 3.2 pg/ml, the 
lowest dilution on the standard curve, was considered to be the lower limit of detection. 
4.2.9. Additional Data 
While leucocyte counts were obtained by means of microscopic visualization in a new Neubauer 
chamber, data about differential counts was provided kindly by the laboratory of Heartlands hospital 
(Birmingham, UK). 
Hemoglobin content of blood samples was measured by means of a hemoglobin-photometer 
(HemoCue Plasma/Low Hb Photometer). By means of a centrifuge (HaematoSpin 1400) and a 
hematocrit reader (Tube reader), hematocrit measurements were obtained.  
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Data sets from the participants´ data collection booklets were provided by the University of Bangor 
(Wales, UK). Data include cold symptoms, Bristol stool scale, resting heart rate, arterial oxygen 
saturation, barometric pressure, and the Lake Louise score (LLS).  
Cold symptoms in the last 24 hours were reported by the participant in person in the evenings 
throughout the entire sojourn. For each of the following items participants gave subjective score 
points with 0 = none, 1 = mild, 2 = moderate, and 3 = severe: sneezing, runny nose, blocked nose, 
sore throat, cough, chilliness, and malaise. 
Gastrointestinal voiding was self-reported on a daily basis by employing the Bristol Stool Scale 
(number of motions per day and consistency of motions on a 1–7-point Likert scale) [119]. 
Resting heart rate and arterial oxygen saturation was recorded both in the mornings while fasted 
and seated for 10 minutes and in the evenings while seated for 10 minutes by means of a pulse 
oximeter (Nonin Onyx 9500). Barometric pressure was read from a wrist watch (Suunto X3HR). 
The LLS was filled in by the participant in person in the mornings throughout the entire sojourn. For each 
of the following five symptoms participants gave subjective score points in increasing severity from 0 to 
3: headache, gut symptoms, fatigue/weakness, dizzy/lightheaded, difficulty sleeping (see table 3).  
 
Table 3 Lake Louise score 
The Lake Louise score uses five symptoms, each scoring from 0 to 3 with increasing severity in order to detect AMS 
[120]. 
  
Score Headache Gastrointestinal symptoms 
Fatigue/ 
Weakness 
Dizziness/ 
Lightheadedness Difficulty Sleeping 
0 None None None None Slept as well as usual 
1 Mild Poor appetite  or nausea Mild Mild Did not sleep as well as usual 
2 Moderate Moderate nausea or vomiting Moderate Moderate 
Woke many times,  
poor night’s sleep 
3 Severe 
Severe nausea  
and vomiting, 
incapacitating 
Severe Severe Could not sleep at all 
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The diagnosis of AMS is based on a rise in altitude within the last four days and the application of the 
scoring system according to the LLS. In order to diagnose AMS, headache is obligatory and at least 
one other symptom of the LLS has to be present (gastrointestinal symptoms, fatigue/weakness, 
dizziness/lightheadedness, difficulty sleeping). Finally, a total score of 3 or more from the 
questionnaire confirms the diagnosis of AMS. 3 to 5 points mean mild AMS and scores of 6 and 
above signify severe AMS. [120, 121] 
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5. Results 
In the following sections results are presented according to the three sets of points of time of data 
collection compared. At first, data from resting subjects was analyzed and sea level (69 m) values 
were related to high altitude (5050 m) values. Furthermore, data from subjects who undertook a 
standardized incremental exercise test was utilized to check values before exercise against values 
180 minutes after cessation of exercise. At last, data obtained from a one-day climb totaling to an 
altitude difference of 1970 meters was evaluated to compare values before ascent with values after 
descent.  
As the major finding, this study found that growth factors showed significant changes predominantly 
when comparing sea level (69 m) values with high altitude (5050 m) values in resting subjects. There 
was no major impact on growth factor levels through exercise both at sea level (69 m) and at high 
altitude (5050 m).  
5.1. Group 1 – Resting at Sea Level (69 m) versus High Altitude (5050 m) 
Table 4 shows data from participants that were at rest [25 at sea level (69 m) and 18 at high altitude 
(5050 m)]. 
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Table 4 Growth factors, differential counts, and additional data of resting subjects at sea level (69 m) versus 
high altitude (5050 m) 
Median (Min; Max) rounded values of 25 subjects are shown [25 at sea level (69 m) and 18 at high altitude (5050 
m)] 
G-CSF granulocyte colony stimulating factor, GM-CSF granulocyte macrophage colony stimulating factor, EGF 
epidermal growth factor, VEGF vascular endothelial growth factor, TGF-β1 transforming growth factor β 1, FGF-2 
fibroblast growth factor 2, IGF-1 insulin-like growth factor 1, IGFBP-1 insulin-like growth factor binding protein 1, 
IGFBP-3 insulin-like growth factor binding protein 3, O2 oxygen, pO2 barometric oxygen pressure, Hb hemoglobin, 
Hct hematocrit, BMI body mass index, NS not significant, NA not available, ↑ increase, ↓ decrease, p p-value 
Variable (units) Sea Level (69 m) High Altitude (5050 m) p ↑/↓ 
G-CSF (pg/ml) 35.5 (14.8; 77.2) 50.3 (21.9; 161.3) 0.029 ↑ 
GM-CSF (pg/ml)  3.2 (1.9; 50.0) 4.0 (1.9; 48.8) 0.035 ↑ 
EGF (pg/ml)  5.8 (2.9; 138.5) 10.7 (3.2; 2047.2) 0.002 ↑ 
VEGF (pg/ml)  160.5 (11.4; 616.1) 362.5 (11.4; 1520.2) 0.039 ↑ 
TGF-β1 (pg/ml)  2566.8 (310.8; 9265.2) 17116.5 (294.0; 75043.2) < 0.001 ↑ 
FGF-2 (pg/ml)  98.9 (3.2; 1057.4) 98.9 (3.2; 1222.2) NS ↑ 
IGF-1 (µg/l)  167 (96.3; 360) 130 (71.8; 212) < 0.001 ↓ 
IGFBP-1 (ng/ml)  8.5 (1.8; 72.7) 9.3 (1.9; 46.1) NS ↑ 
IGFBP-3 (mg/l)  2.6 (1.6; 4.2) 2.1 (0.8; 3.6) < 0.001 ↓ 
Leucocytes/µl  3050.0 (1150.0; 7050.0)  3800.0 (1150.0; 10850.0)  NS ↑ 
Lymphocytes (%) 51.0 (20.0; 72.0)  39.0 (16.0; 64.0)  0.048 ↓ 
Monocytes (%)  3.0 (0.0; 7.0)  4.0 (0.0; 8.0)  NS ↑ 
Neutrophils (%) 45.0 (23.0; 73.0)  56.0 (36.0; 81.0)  0.022 ↑ 
Eosinophils (%) 3.0 (0.0; 12.0)  1.0 (1.0; 4.0)  NS ↓ 
Basophils (%)  3.0 (3.0; 3.0)  NA NA NA 
O2 Saturation (%) 96.0 (74.5; 98.5)  80.0 (61.0; 96.0)  < 0.001 ↓ 
pO2 (mmHg)  760.0 (760.0; 760.0)  554.0 (554.0; 555.0)  < 0.001 ↓ 
Hb (g/l)  140.0 (95.0; 169.0)  159.5 (120.0; 196.0)  < 0.001 ↑ 
Hct (%)  40.0 (29.0; 49.0)  44.3 (36.3; 53.3)  NS ↑ 
BMI  23.3 (19.0; 28.7)  22.9 (18.7; 34.5)  NS ↑  
In subjects that were at rest (group 1), significant changes occurred when comparing sea level (69 m) 
data with values from 5050 m. Factors affected by these changes included G-CSF, GM-CSF, EGF, VEGF, 
TGF-β1, IGF-1, and IGFBP-3. However, no significant changes were observed in FGF-2 and IGFBP-1. 
Analysis of differential counts showed significant changes in neutrophils and lymphocytes. Not 
significantly altered were leucocytes, monocytes, and eosinophils. No information could be obtained 
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about basophil levels because they were below detection ranges. Additionally, O2 saturation and 
partial oxygen pressure along with hemoglobin counts did show significant changes. However, 
neither BMI nor hematocrit changed significantly.  
In resting subjects, a generalized rise of most of the growth factors was observed at high altitude 
(5050 m) when compared to values at sea level (69 m). Of the vascular growth factors investigated, 
EGF (p = 0.002), VEGF (p = 0.039), and TGF-β1 (p < 0.001) showed a significant rise at high altitude 
(5050 m). Although FGF-2 levels decreased at high altitude (5050 m) the changes were not of 
statistical significance. Levels of hematological growth factors G-CSF (p = 0.029) and GM-CSF (p = 
0.035) were significantly higher than at sea level (69 m). Of the insulin axis, IGF-1 (p < 0.001) and 
IGFBP-3 (p < 0.001) showed a significant decrease at high altitude (5050 m), while IGFBP-1 levels 
showed a nonsignificant increase when compared to sea level (69 m) values. Analysis of differential 
blood counts produced significant changes shown by a decrease in lymphocytes (p = 0.048) and an 
increase in neutrophil counts (p = 0.022) at high altitude (5050 m). Finally, significant results of 
additional data include a decrease in partial oxygen pressure (p < 0.001) and oxygen saturation (p < 
0.001), while hemoglobin levels were significantly elevated (p < 0.001) at high altitude (5050 m). 
Table 4 presents all statistically significant data in group 1 subjects. For corresponding box plots see 
figures 12 to 23 in the appendix.  
5.2. Group 2 – Exercise at Sea Level (69 m) versus High Altitude (5050 m) 
Table 5 shows all data of subjects who underwent an incremental exercise step test both at sea level 
(69 m) and at high altitude (5050 m). 
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Table 5 Growth factors, differential counts, and additional data of exercising subjects at sea level (69 m) and 
high altitude (5050 m) 
Median (Min; Max) rounded values of 8 subjects are shown. 
G-CSF granulocytes colony stimulating factor, GM-CSF granulocyte macrophage colony stimulating factor, VEGF 
vascular endothelial growth factor, FGF-2 fibroblast growth factor 2, TGF-β1 transforming growth factor β 1, EGF 
epidermal growth factor, IGF-1 insulin-like growth factor 1, IGFBP-1 insulin-like growth factor binding protein 1, 
IGFBP-3 insulin-like growth factor binding protein 3, O2 oxygen, pO2 barometric oxygen pressure, Hb hemoglobin, 
Hct hematocrit, BMI body mass index, NS not significant, NA not available, ↑ increase, ↓ decrease, p p-value 
 
Variable (units) Sea level (69 m) High altitude (5050 m)  
 Pre 180 min post p ↑/↓ Pre 180 min   post P ↑/↓ G-CSF (pg/ml) 35.5 (14.8; 74.1) 30.5 (21.9; 71.0) NS ↓ 35.5 (25.4; 74.1) 41.3 (21.9; 154.0) NS ↑ 
GM-CSF (pg/ml) 3.2 (3.2; 50.0) 3.2 (3.2; 80.1) NS ↑ 3.2 (3.2; 32.2) 3.2 (1.9; 40.2) NS ↑ 
VEGF (pg/ml) 141.9 (16.0; 431.2) 
122.8  (16.0; 520.4) 
NS ↓ 219.9 (16.0; 1520.2) 
91.7       (16.0; 1101.3) 
NS ↓ 
FGF-2 (pg/ml) 57.5     (3.2;  415.4) 
114.5   (47.8; 372.5) 
NS ↑ 120.2 (63.7; 270.5) 
94.7       (41.5;    181.7) 
NS ↓ 
TGF-β1 (pg/ml) 2908.4 (762.0; 8755.2) 
2050.8 (294.0; 7922.1) 
NS ↓ 9630.9 (2702.7; 17907.3) 
2398.7 (678.3; 8299.2) 
NS ↓ 
EGF (pg/ml) 3.9 (3.2; 18.0) 3.2 (3.2; 15.5) 0.031 ↓ 4.1 (3.2; 25.9) 3.2 (3.2; 21.9) NS ↑ 
IGF-1 (µg/l) 148.5 (102.0; 182.0) 
139.5 (107.0; 209.0) 
NS ↓ 143.0 (91.9; 174.0) 
144.5     (91.3;    211.0) 
NS ↑ 
IGFBP-1 (ng/ml) 8.7 (1.8; 28.0) 13.2 (3.0; 32.0) NS ↑ 8.5 (1.9; 37.3) 8.1 (4.1; 30.3) NS ↓ 
IGFBP-3 (mg/l) 2.3 (1.6; 4.0) 2.9 (1.9; 3.7) NS ↑ 2.1 (1.5; 3.6) 2.5 (1.6; 4.8) NS ↑ 
Leucocytes/µl 3800.0 (2400.0; 6600.0) 
6450.0 (4350.0; 9750.0) 
0.016 ↑ 4125.0 (3400.0; 5400.0) 
7325.0 (5900.0; 16400.0) 
0.008 ↑ 
Lymphocytes (%) 44.0 (20.0; 72.0) 42.5 (14.0; 49.0) NS ↓ 45.5 (30.0; 60.0) 37.0 (32.0; 64.0) NS ↓ 
Monocytes (%) 3.5 (0.0; 5.0) 4.0 (0.0; 12.0) NS ↑ 2.5 (1.0; 9.0) 2.0 (1.0; 4.0) NS ↓ 
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Table 5 continued 
Variable (units) Sea level (69 m) High altitude (5050 m)  
 Pre 180 min post p ↑/↓ Pre 180 min post P ↑/↓ Neutrophils (%) 5.0 (23.0; 65.0) 54.0 (35.0; 81.0) NS ↑ 52.5 (35.0; 59.0) 60.0 (34.0; 68.0) NS ↑ 
Eosinophils (%) 2.0 (0.0; 12.0) 1.5 (1.0; 5.0) NS ↓ 2.0 (1.0; 4.0) 1.0 (1.0; 1.0) NS ↓ 
Basophils (%) NA NA NA NA NA NA NA NA 
O2 Saturation (%) 95.8 (94.5; 97.5) NA NA 86.3 (75.0; 96.0) NA NA 
pO2 (mmHg) 760.0 (760.0; 760.0) NA NA 553.0 (553.0; 555.0) NA NA 
HB (g/l) 144.0 (97.0; 159.0) 
151.0 (103.0; 157.0) 
NS ↑ 166.0 (152.0; 184.0) 
179.5  (150.0; 183.0) 
NS ↑ 
Hct (%) 42.8  (31:0; 45:0) 
40.5   (38.0;  44.0) 
NS ↓ 48.5    (45.5; 51.5) 
NA NA NA 
BMI 23.6 (22.6; 24.8) NA NA 24.7 (21.4; 34.5) NA NA 
AMS 0.0 (0.0; 0.0) NA NA 0.0 (0.0; 0.0) NA NA  
Two factors measured in exercising subjects presented values of statistical significance. While this 
study could show a significant decrease after 180 minutes after exercise at sea level (69 m) for EGF, it 
could not reach a significant magnitude at high altitude (5050 m). Secondly, the leucocyte count 
showed a significant increase 180 minutes after exercise both at sea level (69 m) and high altitude 
(5050 m).  
5.2.1. Sea Level (69 m) – Pre versus 180 Minutes Post Exercise 
Significant changes occurred in EGF (p = 0.031) and leucocytes (p = 0.016). Median (Min; Max) 
rounded values for EGF were 3.9 (3.2; 18.0) pre exercise and 3.2 (3.2; 15.5) 180 minutes after 
exercise (see figure 7). Leucocytes showed a median increase from 3800.0 (2400.0; 6600.0) to 
6450.0 (4350.0; 9750.0) 180 minutes after exercise (see figure 8). 
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Figure 7 EGF – Exercise at sea level (69 m) 
EGF levels changed significantly (p = 0.031) at sea level when levels before exercise 3.9 (3.2; 18.0) were compared 
to levels 180 minutes after exercise 3.2 (3.2; 15.5) [Median (Min; Max) rounded values].  
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Figure 8 Leucocytes – Exercise at sea level (69 m) 
Leucocyte levels changed significantly (p = 0.016) at sea level when levels before exercise 3800.0 (2400.0; 6600.0) 
were compared to levels 180 minutes after exercise 6450.0 (4350.0; 9750.0) [Median (Min; Max) rounded values]. 
 
Nonsignificant changes of growth factors at sea level (69 m) in exercising subjects are shown in the 
synoptical table 5.  
5.2.2. High Altitude (5050 m) – Pre versus 180 Minutes Post Exercise 
At high altitude (5050 m) no significant changes occurred in growth factors when levels before 
exercise were compared with levels 180 minutes after cessation of exercise (see table 5). However, 
leucocytes showed significant changes (p = 0.008) with median (Min; Max) values of 4125.0 (3400.0; 
5400.0) pre and 7325.0 (5900.0; 16400.0) 180 minutes post exercise (see figure 9). 
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Figure 9 Leucocytes – Exercise at high altitude (5050 m) 
Leucocyte levels changed significantly (p = 0.008) at sea level when levels before exercise 4125.0 (3400.0; 5400.0) 
were compared to levels 180 minutes after exercise 7325.0 (5900.0; 16400.0) [Median (Min; Max) rounded values]. 
5.3. Group 3 – Damphus Peak (6035 m) 
No significant changes, neither in growth factors, nor in differential counts nor in additional data, 
could be shown after a bout of intense exercise while climbing Damphus Peak at 6035 m (see table 
6). The difference in altitude from ascent to descent totaled to 1970 meters.   
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Table 6 Nonsignificant changes of growth factors, differential counts, and additional data after a one-day 
climb 
Median (Min; Max) rounded values of 4 subjects are shown. 
G-CSF granulocyte colony stimulating factor, GM-CSF granulocyte macrophage colony stimulating factor, EGF 
epidermal growth factor, VEGF vascular endothelial growth factor, TGF-β1 transforming growth factor β 1, FGF-2 
fibroblast growth factor 2, IGF-1 insulin-like growth factor 1, IGFBP-1 insulin-like growth factor binding protein 1, 
IGFBP-3 insulin-like growth factor binding protein 3, O2 oxygen, pO2 barometric oxygen pressure, Hb hemoglobin, 
Hct hematocrit, NS not significant, NA not available, ↑ increase, ↓ decrease 
 Variable (units) Pre Post p  ↑/↓ 
G-CSF (pg/ml) 33.0 (28.8; 45.4)  42.1 (38.8; 67.8)  NS ↑ 
GM-CSF (pg/ml)  3.2 (1.9; 5.0)  3.2 (3.2; 5.6)  NS ↑ 
EGF (pg/ml)  14.1 (11.2; 18.0)  10.8 (5.5; 13.4)  NS ↓ 
VEGF (pg/ml)  16.0 (11.4; 338.3)  16.0 (16.0; 386.8)  NS ↑ 
TGF-β1 (pg/ml)  23620.8 (4891.8; 39217.2)  11647.2 (9463.2; 14625.3)  NS ↓ 
FGF-2 (pg/ml)  22.3 (3.2; 80.9)  71.0 (34.2; 155.8)  NS ↑ 
IGF-1 (µg/l)  178.0 (162.0; 209.0)  173.0 (133.0; 213.0)  NS ↓ 
IGFBP-1 (ng/ml)  7.8 (4.7; 14.2)  15.2 (7.1; 24.1)  NS ↑ 
IGFBP-3 (mg/l)  3.0 (2.4; 3.6)  2.3 (2.0; 2.7)  NS ↓ 
Leucocytes/µl  5250.0 (3300.0; 6300.0)  9550.0 (6450.0; 14400.0)  NS ↑ 
Lymphocytes (%) 49.0 (39.0; 60.0)  24.0 (24.0; 24.0)  NA NA 
Monocytes (%)  7.0 (5.0; 9.0)  3.0 (3.0; 3.0)  NA NA 
Neutrophils (%) 39.5 (33.0; 46.0)  72.0 (72.0; 72.0)  NA NA 
Eosinophils (%) 4.5 (2.0; 6.0)  1.0 (1.0; 1.0)  NA NA 
Basophils (%)  NA NA NA NA 
O2 Saturation (%) NA NA NA NA 
pO2 (mmHg)  553.0 (553.0; 553.0)  553.0 (553.0; 553.0)  NS → 
Hb (g/l)  170.0 (160.0; 182.0)  175.0 (175.0; 175.0)  NA NA 
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6. Discussion 
In recent years, substantial progress has been made toward the identification and understanding of 
the molecular environment generated by growth factors. The data this study produced provides 
insight into hypoxia- and exercise-induced modifications of growth factor levels.  
The main aim of this study was to test the novel idea that members of all major growth factor 
groups, i.e. vascular growth factors, hematological growth factors and growth factors appertaining to 
the IGF-network are affected in concert by hypobaric hypoxia. To our knowledge, this study is the 
first to investigate the regulation of circulating growth factors in humans when exposed to hypobaric 
hypoxia compared to normobaric normoxia and effects of physical exercise under these 
circumstances. For latter, the time course of changes in the concentrations of serum growth factors 
before and after a standardized incremental step test both at sea level (69 m) and at high altitude 
(5050 m) was therefore examined. 
As the major finding, growth factors showed significant changes predominantly when concentrations 
at sea level (69 m) were compared to high altitude (5050 m) values. While hypoxia generated 
pronounced effects on the growth factor milieu in resting subjects (group 1), exercise did not elicit 
significant changes in most growth factors at sea level (69 m) (group 2). At high altitude (5050 m), 
exercise in hypobaric hypoxia (group 2) did not produce any significant changes in growth factor 
levels. Growth factors measured at 5050 m both before and after return from a summit (6035 m) 
approach (group 3) did not show any significant changes, either.  
This study adds valuable data to the understanding of mechanisms of growth factor regulation in 
humans. New insights are applicable to the understanding of the pathophysiology of clinical 
conditions such as chronic lung and/or heart disease or tumor pathologies as well as potential new 
treatment strategies. Furthermore, insights may be used to improve altitude training employed by 
athletes, pilots, or military personnel.  
 
In the subsequent sections, methodological aspects and findings of the present study are contrasted 
with those of other studies and discussed below. 
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6.1. Methodological Aspects 
The employment of Luminex xMAP multiplex assay system deserves recognition as a methodological 
disparity when contrasting findings of this study to those that have utilized other assays with 
different limits of detection. As a consequence, statistical reports with respect to means, standard 
deviation, medians, minimum and maximum values, interquartile ranges, and percent changes may 
not be directly comparable. Owing to the fact that manufacturers constantly produce improved 
products and thus provide researchers with more sensitive and/or more specific assays, assay 
specifications have to be taken into account when comparing results across studies. For instance, the 
assay used in this study is now available with higher sensitivity and specificity, which was not at 
disposal at the time the study was carried out. Furthermore, instead of running samples repeatedly, 
each sample was analyzed only once. This method holds the danger of missing inter- and intra-assay 
variations.  
 
In comparison to other studies such as the one of Laufs et al. who employed only young and healthy 
men [122], the present study conducted exercise tests also in healthy, moderately active subjects but 
they represented a more heterogeneous group with relation to both age (median 37.5 years) and sex 
(3 women and 5 men). This adds to the representativeness of this study. 
 
It is important to note that the time course of changes in tissue oxygenation does not necessarily 
correspond with changes in serum levels of growth factors. The lack of significant changes in growth 
factor levels may be due to removal from the circulation by rapid receptor binding [123]. Moreover, 
up- or down-regulation of growth factors may be on a local level via autocrine/paracrine signaling 
rather than on a systemic level via endocrine signaling [38, 52, 124]. 
 
Furthermore, growth factors produced locally might not only translocate to the systemic circulation 
but also to the lymphatic system. Although lymphatic vessels ultimately join blood vessels, growth 
factor levels are likely to be modulated at sites of high concentrations of immunological cells such as 
lymph nodes. [125] 
 
A further benefit of this study is that this study was conducted under hypobaric hypoxic conditions 
at high altitude (5050 m) instead of under controlled environmental conditions in so-called 
Discussion 
47 
(normobaric) hypoxia chambers. Since participants of the study were obligated to multiple varying 
stressors including psychological stress, environmental extremes, disturbed sleep architecture, 
malnutrition, and weight loss, this study is more representative for clinical conditions including AMS, 
HAPE, HACE, chronic obstructive pulmonary disease (COPD), and congestive heart failure, just to 
name a few.  
6.2. Discussion of Results 
The following section will illuminate the role of growth factors in a hypoxic environment and in 
response to physical activity.  
6.2.1. Growth Factors and Hypoxia 
The present study investigated whether there is a change in concentrations of growth factors under 
hypobaric hypoxia at high altitude (5050 m) when compared to normobaric normoxia at sea level (69 
m) values. The expedition´s altitude profile allowed for adequate acclimatization since maximum 
daily increase of altitude where participants slept amounted to 300 meters. Nonetheless, about 25 % 
of participants suffered from acute mountain sickness on the day after arrival at base camp (5050 
m). This phenomenon and other signs of reduced immune function such as impaired wound healing 
are common traits in mountaineers at high altitude. Other than that, Walsh et al. allege that high 
altitude appears to have no further marked effects on immune function. [126] The present study, 
however, very well proved that hypoxia affects neuroendocrinological and immunological responses. 
This is represented, in part, by the increase of vascular growth factors including EGF (p = 0.002), 
VEGF (p = 0.039), and TGF-β1 (p < 0.001).  
The present study is in line with previous studies proving that exposure to high altitude (5050 m) 
hypobaric hypoxia potently stimulates the production of EGF which rose in the present study 
significantly (p = 0.002). EGF is involved in cellular events such as resistance to apoptosis, 
proliferation, and migration of pulmonary vascular cells. Investigations of clinical conditions such as 
pulmonary arterial hypertension (PAH) could also prove a strong association with elevated EGF levels 
[20]. By linking hypoxic EGF-induction in our field study with the role of EGF in PAH this study 
substantiates clinically present effects of hypoxia on a molecular level. 
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The present study showed that there is a significant rise in VEGF concentrations at high altitude 
(5050 m) when compared to sea level (69 m) in resting subjects (p = 0.039). This is in line with 
previous studies [127, 128]. Moreover, validity of this study´s data is confirmed by studies of Heits et 
al. who investigated VEGF concentrations in healthy humans under resting conditions[129] and 
Gunga et al. [48] who gave similar ranges of VEGF alterations.  
The reason for these findings is given by the fact that hypoxia is a potent stimulator of growth factor 
release. VEGF is one of the key factors of angiogenesis and vascular development in the setting of 
tissue hypoxia which is mediated by HIF-1α. VEGF-mediated capillarization enhances the delivery of 
oxygen in peripheral tissues and thus aids adaptation to hypoxia [32, 43] Furthermore, hypoxia is 
known to up-regulate pro-inflammatory cytokines such as IL-6 which in turn is known to increase 
VEGF levels [130]. Therefore, it can be argued that increases in VEGF levels are triggered not only 
directly by hypoxia but also indirectly via the hypoxia-mediated initiation of inflammatory processes 
[130].  
 
Hypoxia induces epithelial to mesenchymal transition in a TGF-β1-dependent manner and raises the 
ratio of bioactive to total levels of TGF-β1 [76]. The present study is in line with previous studies [76, 
131] and confirms a significant rise of TGF-β1 plasma levels in resting subjects at high altitude (5050 
m) when compared to sea level (69 m) data (p < 0.001). 
 
Various reports confirm that hypoxia induces FGF production causing proliferation of vascular cells 
[20, 124, 132] and facilitates responsiveness of endothelial cells to FGF-2 [133]. In the present study, 
however, changes in FGF-2 levels were not significant. One reason could be that opposing factors 
interfere with FGF-2 production. Indeed, IGF and TGF-β1 intertwine with FGF-2 at certain points of 
their signaling pathways [55]. TGF-β1 opposes hypoxia-induced FGF-2-mediated growth promoting 
effects [41] and therefore it may be that increased levels of TGF-β1, as seen in the present study, 
interfere with FGF-2 at an earlier stage of signal transduction. 
 
In the present study, hematological growth factors, both G-CSF (p = 0.029) and GM-CSF (p = 0.035), 
showed a significant rise at high altitude (5050 m) when compared to sea level (69 m). This is 
substantiated by clinical studies investigating hematological growth factors in hypoxic conditions. In 
cerebral ischemia, it has been shown that both G-CSF and G-CSF receptor are up-regulated in 
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neuronal cells. Neuronal injury due to hypoxia elicits G-CSF release which represents a 
neuroprotective mechanism because G-CSF promotes neurogenesis and angiogenesis [79, 134]. 
Since high altitude induces multiple processes involving the immune system and endocrinological 
system, it is difficult to identify whether changes are triggered by either hypoxia or the initiation of 
inflammatory processes, or both. 
To our knowledge, this study is the first to describe a direct correlation between increasing GM-CSF 
levels upon exposure to low levels of atmospheric oxygen. GM-CSF was significantly elevated at high 
altitude (5050 m) when compared to sea level (69 m). A possible explanation for the increase in both 
G-CSF and GM-CSF under hypoxic conditions is the fact that both factors are key regulators of the 
production of erythroid and megakaryocytic progenitor cells [91, 135-137]. Both types of progenitor 
cells have been identified to be up-regulated under tissue hypoxia[1, 138]. The purpose of up-
regulation of GM-CSF remains to be investigated. It can be assumed, however, that increased levels 
of GM-CSF bolster the generation of both immunologically active cells and cells involved in enhanced 
tissue oxygenation (as seen in erythropoiesis).  
 
The present study found significant decreases in IGF-1 (p < 0.001) and IGFBP-3 (p < 0.001) in resting 
subjects upon exposure to high altitude (5050 m). Hansen et al. found no changes in IGF-1 or IGFBP-
3 in vertebrate embryonic cells under hypoxia [139]. Yamada et al. showed increases in IGFBP-3 
mRNA upon exposure to both increasing levels of hypoxia and hypoxic exposure time [98]. The 
present study describes changes in the IGF axis in serum blood, while the other two studies targeted 
embryonic cells and mRNA products, respectively. While the studies of Hansen et al. and Yamada et 
al. present in vitro data of the IGF axis, the present study illustrates in vivo changes of the IGF axis. 
Since all studies looked at the IGF axis on a different level, findings might rather complement than 
contradict each other.  
On the one hand, the present study found no significant changes in IGFBP-3 levels after physical 
exercise both under normoxia and hypoxia, on the other hand, resting subjects showed a significant 
decrease of IGFBP-3 concentrations upon exposure to hypoxia (p < 0.001). Considering this study´s 
findings and the study of Hug et al. [140], hypoxia appears to be the crucial factor to produce 
significant changes in IGFBP-3, while exercise seems to play a minor role.  
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Since both IGF-1 (p < 0.001) and IGFBP-3 (p < 0.001) decreased significantly under hypoxia, data of 
the present study is in line with previous findings that stated that IGF-1 and IGFBP-3 are positively 
correlated [100].  
Previous reports stated that IGFBP-1 is up-regulated via HIF-1 upon exposure to hypoxia [108, 109]. 
Furthermore, Arafat et al. stated that IGFBP-1 and IGF-1 are negatively correlated. [100] Therefore, 
decreasing IGF-1 levels, as seen in the present study (p < 0.001), are associated with increasing 
IGFBP-1 levels. Even though IGFBP-1 was not significantly changed under hypoxia, there was a 
tendency towards elevated IGFBP-1 levels. Woods et al. confirmed that resting morning cortisol 
levels are elevated at high altitude (> 5000m) [141]. Taking into account that Cianfarani et al. 
reported that cortisol is positively correlated with IGFBP-1 and negatively correlated with IGF-1 
[142], potentially elevated cortisol levels at the time of blood sampling would explain this study´s 
findings of not significantly increased levels of IGFBP-1 and significantly decreased levels of IGF-1 (p 
< 0.001) in resting subjects at high altitude (5050 m). One possible explanation of IGF-1 reduction at 
high altitude (5050 m) is that increased cortisol concentrations reduce proteolysis of IGFBP-3 and 
thus increase IGFBP-3 levels. Since IGFBP-3 binds IGF-1, the net effect is reduced IGF-1 bioavailability 
[104]. 
6.2.2. Growth Factors and Exercise 
While there are many studies that investigated either hypoxia-induced or exercise-induced changes 
in growth factors, there are few studies that have investigated changes in growth factor 
concentrations after physical exercise in hypobaric hypoxia. Summarized insights of various studies 
lead to the assumption that exercise amplifies the immunosuppression imposed by tissue hypoxia 
and that growth factors play a role in this setting. [6, 127] In the present study, hypoxia at rest 
caused significant changes in most growth factors, additional stress through exercise, however, failed 
to cause significant changes in most growth factors both at sea level (69 m) and high altitude (5050 
m) (see tables 4 and 5, respectively).  
 
The present study investigated whether there is a change in growth factor levels after physical 
exercise when compared to resting values. Neither the 12-minute exercise protocol applied both at 
sea level (69 m) and at high altitude (5050 m), nor a 12-hour climb from Hidden Valley Base Camp 
(5050 m) to Damphus Peak (6035 m) and back produced significant changes in growth factor levels. 
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Prolonged physical activity, as seen in endurance exercise, produces large changes in plasma levels of 
cytokines (e.g., increases in IL-6, IL-8, and IL-10 [143] and increases in IL-1rα, TNF-α, and IL-1β [144]) 
and it is therefore likely that it affects all growth factors investigated. However, in the present study a 
prolonged physical activity represented by a 12-hour journey (ascent from 5050 m to 6035 m and 
subsequent descent to 5050 m) failed to produce significant changes in growth factors. This is likely 
to be caused by too small a sample size (4 subjects) to produce significant conclusions. 
 
In the present study short term exercise (12 minutes) did not produce significant changes in growth 
factor levels, neither at sea level (69 m), nor at high altitude (5050 m). One reason could be that 
during an exercise bout of 12 minutes there is not enough time to generate a considerable 
magnitude of oxidative stress and energy demand, i.e. represents a too weak stimulus to elicit 
significant changes. 
 
In addition, the rate of clearance of growth factors from the circulation into the urine after exercise 
seems to affect their plasma concentrations. In that sense, it is reasonable to presume that, when 
compared to short-term exercise, prolonged physical activity causes a stronger redistribution of 
systemic blood flow to exercising muscles. This exerts more pronounced restrictions on renal blood 
flow which in turn causes a prolonged inhibition of the clearance of growth factors from circulation. 
[11, 145, 146] Accordingly, it is assumed that the longer the period of exercise, the slower the 
clearance of growth factors from the circulation and thus the higher growth factor concentrations 
after exercise. Taking into account that the present study employed an exercise bout of 12 minutes it 
can be assumed conversely that absent significant changes in growth factor levels owe to too short a 
duration of physical activity. In other words, plasma growth factors are presumably cleared too fast 
from the blood stream during and after short term exercise to be detected in significant amounts.  
Accordingly, it can be assumed that during the 12-minute incremental step test growth factors travel 
from blood to peripheral tissues, therefore measurements reveal at this point reduced plasma levels 
of growth factors. In the post-exercise phase pre-exercise plasma levels are restored by migration of 
growth factors from bone marrow to the circulation. [147] Further studies are needed in order to 
investigate clearance of growth factors from circulation.  
Another issue is exercise-induced ischemia of the gastrointestinal tract which could result in 
disintegration of gut mucosa and bacterial invasion into the systemic circulation. Bacteremia might 
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result in elevated levels of endotoxin lipopolysaccharide [145, 148] which is a potent stimulant of 
immunological responses including changes in growth factors. [149, 150] In consideration of this 
mechanism, endurance exercise is more likely to induce bacterial translocation than short-term 
exercise, as employed in the present study, which may be another reason for nonsignificant changes 
of growth factors in the present study. 
 
Other putative mechanisms for undetected growth factor changes are on the one hand a restricted 
systemic release of growth factors in response to exercise-induced tissue hypoxia, on the other hand 
a very short half-life of growth factors in the systemic circulation.  
It has been shown that exercise negatively influences cellular immunity by reducing circulating 
numbers of T- and B-lymphocytes. Amongst others, these changes are related to alterations in the 
balance of the growth factor milieu. To date, the clinical significance of these immunological changes 
in response to exercise lack explanation. [151] 
 
In agreement with the notion that suppression of the immune system is induced by physical exercise 
which in turn increases susceptibility to symptoms of infection such as upper respiratory tract 
infection, cellular changes are observed during and immediately after exercise.  
 
With respect to differential blood counts, this study´s findings confirm previous reports of a marked 
lymphocytosis after exercise [151]. Leucocytes were both at sea level (69 m) (p = 0.016) and at high 
altitude (5050 m) (p = 0.008) significantly elevated 180 minutes after cessation of exercise. Walsh et 
al. pointed out that leucocytes drop below pre-exercise levels during the early stages of recovery and 
levels return to resting values within 24 hours [126]. This leads to the conclusion that immunological 
changes are in progress even 180 minutes after cessation of exercise.  
Various reasons for nonsignificant changes in other factors of the differential count after exercise 
exist. Since, for instance, the magnitude of the increase in neutrophils is subject to intensity and 
duration of exercise [151], it can be assumed that an incremental physical exercise of a total duration 
of 12 minutes is insufficient to produce pronounced changes even 180 minutes after cessation of 
exercise. Other reports argue that down-regulation of the neutrophil response after an ascent to 
high altitude (in this case from 1780 m to 3198 m) serves to prevent exercise-induced inflammatory 
destruction of tissues that might otherwise be aggravated by cytotoxic effects of neutrophils [152]. 
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Acute exercise triggers a monocytosis which persists only for about 120 minutes [151]. In the 
present study, post-exercise samples were taken 180 minutes after cessation of exercise. It is 
possible that if levels of monocytes were initially increased, they had already returned to baseline 
levels at 180 minutes after cessation of exercise and therefore no significant changes could be 
measured.  
 
VEGF has been shown to have inflammatory [41] and angiogenic [30, 48] effects upon exercise. This 
study adds novel data to the scarce knowledge about changes in the production and release of VEGF 
upon exercise under different environmental conditions. This study´s data is in line with previous 
reports with respect to basal VEGF concentrations [48, 129] ranging at rest from 2.93 to 138.49 
pg/ml at sea level (69 m).  
Furthermore, this study could verify previous findings of other reports of unchanged plasma 
concentrations of VEGF after exercise [48, 122, 147, 153].   
Even though the scope of the incremental step test employed was not identical with a marathon 
race or a 1500 m run as employed by Bonsignore et al. [147] or 30 minutes of intensive running as 
employed by Laufs et al. [122], this study shares the same findings. Möbius-Winkler et al. employed 
an exercise protocol similar to ours (incremental graded exercise on a cycle ergometer) and were 
able to show an initial significant rise in VEGF levels 10 minutes after exercise, which lost statistical 
significance already 15 minutes post exercise, however [154]. This again complies with the present 
study which found no significant changes of VEGF levels 180 minutes after cessation of exercise. 
Contrasting this study´s findings, two other studies reported a significant decrease of VEGF levels 
immediately after a marathon race of which one took place at sea level [143] and the other at high 
altitude [48]. The decrease in VEGF levels after exercise compared to pre-exercise data may be 
explained by a concomitant increase in levels of VEGF binding proteins (sVEGFR-1) and an increased 
binding affinity of VEGF to its receptors at the endothelium [155, 156]. A possible explanation for 
unchanged concentrations of VEGF in the present study is a concomitant rise in endogenous 
corticosteroid levels which inhibits VEGF release [48]. 
It is well documented that VEGF is a mediator of ischemia-induced regulation of endothelial 
progenitor cells (EPC) [122]. Interestingly, analogous to the present study´s results that exercise did 
not change VEGF levels, Laufs et al. found that exercise was not correlated with VEGF-induced EPC 
regulation. Since this study proved, however, that hypoxia alone produces a significant increase in 
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VEGF levels (p = 0.039), this study disproves Laufs et al. who state that it is not likely that ischemia 
plays also a role in the exercise-induced EPC up-regulation [122].  
A systematic review by da Silva and coworkers features a list of studies dealing with exercise- and 
hypoxia-induced changes of VEGF. Studies treated the issue of exercise-induced mobilization of EPC 
as a marker of vascular repair and angiogenesis which is, at least partly, VEGF-dependent. EPC 
mobilization is more pronounced in long and ultra-long duration exercises (e.g., half-marathon, 
marathon, ultramarathon training) than in maximum exercise regimens (e.g., conventional 
cardiopulmonary exercise test) or submaximum exercise regimens (utilizing a certain percentage of 
the anaerobic threshold and/or maximum VO2max as reference with a maximum duration of one 
hour). Furthermore, while VEGF plasma levels changed significantly in studies using long/ultra-long 
duration exercise protocols, most studies using maximum intensity exercise did not show significant 
changes in VEGF plasma levels. [157] This is in line with this study, since no significant changes in 
VEGF in the groups undergoing maximum (Damphus peak group 3) or submaximum exercise (12-
minute incremental step test) were found. Additionally, long duration exercise was represented by 
the ascent to base camp (5050 m) which lasted 14 days and produced significant changes in most 
growth factors including VEGF (p = 0.039). This leads to the assumption that in the present study 
maximum and submaximum exercise protocols were too low in intensity and/or too short in 
duration to produce significant changes in the growth factor milieu [157]. 
This study complies furthermore with Gunga et al. who also did not find changes in VEGF 
concentrations after physical exercise in normobaric normoxia. In contrast to the present study, they 
showed a decrease of VEGF immediately after a marathon run at high altitude (12 participants 
running 42.2 kilometers (km) each, each one starting at a different altitude ranging from sea level up 
to 4722 m). [48] Arguably, this may be only an immediate response which changes direction in the 
hours following physical exercise. In fact, the study of Schobersberger et al. reports a rise in VEGF 
levels which persists even five days after an ultramarathon (distance 67 km, peak altitude 2739 m, 
altitude difference 2300 m) [130]. Asano et al. showed a biphasic trend of VEGF levels with an initial 
decrease after altitude training at 1886 m at day 10, followed by an increase which reached peak 
values at day 19 of the regimen. VEGF levels returned to normal by 1 month after return to sea level. 
[158] In the present study, VEGF levels significantly increased upon exposure to hypoxia (p = 0.039) 
but did not change after exercise at sea level (69 m) or high altitude (5050 m). Therefore, this study 
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provides valuable data for the identification of triggers of VEGF changes. Thus, it can be assumed 
that hypoxia has a more potent effect on VEGF levels than exercise.  
Multiple studies have been conducted investigating exercise and subsequent changes in immune 
response and growth factors, respectively. Unlike most research projects, this study targeted not 
only VEGF but also other growth factors, thus widening the view upon alterations in growth factors 
involved in exercise. Morici et al. found that VEGF and TGF-β1 levels did increase after exercise [159]. 
However, this study found that VEGF and TGF-β1 do not change significantly after exercise. 
 
Hematological growth factors including G-CSF and GM-CSF did not change significantly upon physical 
exercise. This study´s findings are supported by other studies which did not show significant changes 
in G-CSF after exercise [159, 160] and by Suzuki et al., who did not find statistically relevant changes 
in GM-CSF levels directly after exercise, either [11]. However, Suzuki et al. presented data about 
elevated levels of G-CSF in two separate studies. The first study confirmed increased levels of G-CSF 
10 minutes after a marathon race [11]. The second study confirmed G-CSF up-regulation both 30 
minutes and 14-20 hours after an Ironman triathlon race (maximum race time 10 hours and 30 
minutes) [87]. In a third study Suzuki et al. demonstrated that both endurance and short-duration 
exercise promotes the secretion of G-CSF, M-CSF, IL-8, and MCP-1. Furthermore, they highlighted 
that changes of mentioned growth factors and cytokines are more prominent in urine than changes 
seen in blood plasma. [145] One explanation of the discrepancy towards this study´s findings may be 
the fact that the exercise protocol employed (exercise time of 12 minutes) did not reach intensity 
levels of a marathon or Ironman triathlon race.  
 
Although Hirose et al. showed that 12 minutes of eccentric exercise of elbow flexors induced 
significant muscle damage (rises in creatine kinase and myoglobin), changes in cytokines in general 
were relatively small. However, G-CSF levels were significantly increased 1 hour, 3 hours, and 3 days 
post exercise. [125] 
 
Multiple studies corroborate exercise-induced subclinical states of severe inflammatory response 
syndrome (SIRS) characterized by an amplified cytokine response. Physical exercise induces muscular 
damage as characterized by increasing levels of creatine kinase and myoglobin and promotes the 
release of various factors such as cytokines and growth factors (e.g., G-CSF) [11]. As stated before, G-
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CSF plays a dual role (both pro- and anti-inflammatory effects) in immunomodulation of physical 
exercise. 
 
With regard to the IGF axis the present study found no significant changes in levels of IGF-1, IGFBP-1, 
and IGFBP-3 upon physical exercise, neither at normoxia, nor at hypoxia.  This is in line with the 
studies of Hug et al., who examined elite cyclists and did not find significant changes in IGFBP-3 
levels after exercise under normoxic conditions [140] and Spruit et al., who examined COPD patients 
on a cycle-ergometer under normoxic conditions and did not find significant changes in IGF-1 levels, 
either [161].  
On the one hand, it has been shown that exercise suppresses GH causing a decrease in IGF-1 levels 
[99], on the other hand, there is evidence that exercise induces GH release engendering an increase 
in IGF-1 concentrations [98]. In addition, contradicting reports describe either a decrease or a 
nonsignificant increase in IGF-1 during long-term exercise [162-164].  
Physical exercise reduces the IGF-1/cortisol ratio in athletes, which suggests an increase of catabolic 
processes due to physical exercise [165]. Moreover, exercise under hypoxic conditions induces 
IGFBP-3 down-regulation [140], which causes a concomitant decrease of IGF-1 levels [100]. 
Various studies support the hypothesis that an acute bout of physical activity increases energy 
expenditure and thus increases pro-inflammatory cytokine levels, which in turn decrease IGF-1 
levels. After successful adaptation, pro-inflammatory cytokine levels decrease and entail a rise in 
IGF-1 levels even higher than before exercise which represents an “anabolic rebound”. [166] 
Additionally, about 8 to 30 hours elapse between the release of growth-hormone-releasing factor 
from the hypothalamus and ultimate IGF-1 release. Thus it can be deduced that local changes in IGF-
1 do not reflect systemic changes. [161] This shows that after physical activity changes in IGF-1 levels 
are time-sensitive and that in this study significant systemic changes of IGF-1 might not have been 
detected by data analysis 180 minutes post exercise. In order to gain more insight into changes of 
IGF-1 in both systemic and local levels, future studies are needed which incorporate muscle biopsies 
into their methodology. Furthermore, it can be assumed that initial decreases of systemic IGF-1 
levels do not mirror local levels of IGF-1 which might be higher upon acute physical exercise [166]. 
With regard to that, in the present study, absent changes in IGF-1 may be also explained by the fact 
that local production of IGF-1 in skeletal muscle is increased without having any effects on systemic 
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levels of IGF-1. This underscores the differences in autocrine/paracrine signaling and endocrine 
signaling of growth factors. [93] 
Another explanation for the present study not to show significant changes in IGF-1 levels might be a 
relative GH insensitivity, i.e. IGF-1 levels do not increase albeit the presence of increased GH levels 
[167, 168]. 
As stated above, IGF-1 levels are altered by nutritional states [94, 99]. Proportional to GH levels, IGF-
1 levels are highest at puberty and gradually decline during adulthood [99]. Despite a relatively low 
mean age of participants of 28.5 years, it has to be taken into account that age-related differences in 
the GH set-up have not been accounted for by this study.  
In the present study, the mean BMI of subjects was 23.33. Whether or not BMI influences IGF-1 
levels is controversially discussed. Both decreased and increased levels of IGF-1 have been found in 
obese subjects when compared to non-obese individuals [169]. Additionally, the study of Viesti A. 
Collares et al. pointed out that IGF-1 levels differ in different tissues. For instance, while IGF-1 levels 
were higher in subcutaneous fat of obese subjects (BMI 47.46) when compared to the control group 
(BMI 24.04), this relation was reversed in visceral fat. [169]   
6.3. Limitations of the Study 
The power of the present study and thus its representativeness was weakened by the fact that total 
numbers of participants differed in the 3 groups. This is paradigmatic for field studies especially 
when performed in remote areas and under severe psychological and physical stress. Individual 
subjects voluntarily took part in either all groups or two or only one and some subjects only took 
part at sea level (69 m) but not at high altitude (5050 m). This was due to differing reasons including 
exhaustion, illness, or intake of drugs which then met exclusion criteria.  
 
At high altitude (5050 m), due to dependency on solar power and limited access to electricity, 
samples were spun for 5 instead of 10 minutes at a relative centrifugal force of 12,000 x g. 
Furthermore, due to malfunctions of the centrifuge on day 15 (see figure 4), samples taken that day 
could not be centrifuged but were handled in the following way instead: After phlebotomy blood 
sample tubes were left in a vertical position for sedimentation. After 1 hour the supernatant was 
pipetted into test tubes of 1.5 ml in volume and put in the freezer at -26˚C. These circumstances are 
paradigmatic for aggravating conditions for scientific research in remote areas such as high altitude. 
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In group 3 subjects, blood was sampled at 3:30 a.m. which contrasts sampling times of the day in 
groups 1 and 2 (between 8 a.m. and 3 p.m.). While diurnal variation in cortisol release potentially 
influences growth factor levels [170], Laufs et al. did not find changes in cortisol or VEGF levels after 
a 30 minute exercise trial [122]. However, neither member of group 2 nor of group 3 did present 
major changes in growth factor levels after physical exercise. This is in line with Peake et al. who did 
not find significant changes in growth factor levels after exercise, even though the potential 
influence of diurnal variation of cortisol was minimized by conducting all trials between 11:00 a.m. 
and 12:00 p.m. [160]. 
 
This study was part of a broader range of investigations. Some subjects took part in both the present 
study and other research projects. For instance, one project asked subjects to drink carbohydrate 
supplements [171] in order to assess energy balance which plays a major part in hormonal and 
immunological processes [140, 172, 173]. Another group asked subjects to inhale iloprost while 
performing a cycle ergometer test. Both studies were double-blinded and have potential effects on 
exercise performance and thus also bear the potential to alter hormonal and immunological 
processes with respect to growth factors.  
The present study is potentially confounded by subjects who received alimentary carbohydrate 
supplementation. Thissen et al. found that malnutrition leads to decreased IGF-1 levels [174] and 
Freedland et al. confirmed these findings in a mouse model via deprivation of alimentary 
carbohydrate [175]. Freedland et al. also found the absence of alimentary carbohydrate produced 
higher IGFBP-3 levels and a lower IGF-1:IGFBP-3 ratio when compared to mice with normal 
(Western) or reduced carbohydrate intake [175]. However, firstly little is known about normal ranges 
of variation of IGF-1, IGFBP-2, and IGFBP-3 levels [176] and secondly total energy intake and 
expenditure is strongly correlated with body size, the extent of physical activity, and metabolic 
efficiency. Therefore, it is not clear to what extent carbohydrate supplementation interacts with the 
IGF axis. Underfeeding is much more potent in decreasing IGF-1 levels than overfeeding is in 
increasing IGF-1 levels [177]. Since subjects experienced severe physical stress during the entire 
sojourn which was associated with weight loss, carbohydrate supplementation rather attenuated 
reduced alimentation rather than producing hyperalimentary states. Therefore, potential 
interactions of increased carbohydrate intake with growth factor levels of the IGF axis are if at all of 
minor magnitudes.  
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This study is potentially confounded by subjects who inhaled Iloprost which possesses anti-
inflammatory and immunomodulating actions. Considering that subjects participated in the present 
study at least 24 hours after inhalation of Iloprost and that inhaled Iloprost has a maximum duration 
of action of 60 minutes [178], potential interactions of Iloprost with growth factors at time of blood 
sampling are if at all of minor magnitudes. Another fact adds to the small (if at all present) effects of 
Iloprost on growth factor levels found by previous studies [179-182]. In the present study, subjects 
inhaled Iloprost over several minutes instead of receiving it intravenously or orally over several days 
or implementing animal or cell culture models as applied in cited studies. 
 
Potential confounders which might influence growth factor levels include, but are not limited to, 
genetic determinants [48], gender [4, 93], age, alcohol use, and hormone replacement therapy 
[183].  
6.4. Conclusion and Recommendations 
The human organism is subjected to multiple stressors when going to high altitude. Physical exercise 
amplifies the stress imposed on the human body. Clinical symptoms of disease may be reflected on a 
cellular level by altered levels of growth factors. Whether underlying pathological processes involve 
infectious agents or not is not clearly identifiable. Muscle damage as well as adaptive mechanisms 
may share the same growth factor signaling pathways as the immunological response towards 
infection. Hormonal, endocrinological, neurological and immunological responses might signal via 
idiosyncratic as well as collectively utilized pathways at the same time. Current knowledge is not 
sufficient in order to provide a holistic view of physiological and pathophysiological implications of 
growth factors and their network. However, this study contributes to the understanding of intricate 
growth factor-mediated processes. 
Since host survival depends on efficient immune functions, the immune system has evolved 
redundant processes in order to provide for maximum safety. Redundancy complicates clear 
identification of mechanisms involved in immune function. It remains to be investigated how great 
the loss or gain of immune function has to be in order to produce changes in host defense and 
disease susceptibility or severity. [151] 
Given the fact that growth factors are pleiotropic and form part of a highly complex network, not 
only absolute changes in growth factor concentrations but the contextual dependence has to be 
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taken into account when interpreting these processes. Stressors such as hypoxia or exercise 
engender dynamic effects disturbing the homeostasis of the growth factor network. Paradigmatic is 
the effect of TGF-β on CD4+ T-lymphocyte differentiation. TGF-β alone causes differentiation of TH0-
lympocytes (non-polarized) towards regulatory T-lymphocytes. TGF-β in concert with IL-6, however, 
drives the differentiation of TH0-lympocytes towards TH17-lympocytes [65]. 
High altitude represents an environment where multiple stressors affect the human immune 
response. The altitude-induced change of many growth factors measured in the present study 
provides evidence that subacute exposure to hypoxia tends to stimulate the neuroendocrine and 
immune system. Controversial reports give an account of equivocal immunological processes 
initiated upon exposure to hypobaric hypoxia [152]. Furthermore, changes in the growth factor 
milieu cannot clearly be assigned to immunological or metabolic processes. While, for instance, 
chronic changes in blood concentrations of growth factors appear to give an account of activated or 
inhibited cell growth, migration, or chemotactic attraction of cells, it remains to be shown whether 
(sub)acute changes in growth factors levels reflect the same processes or are representative for a 
new concept of growth factor interactions with respect to hormonal, endocrinological, and 
immunological processes. Further investigation is needed to elucidate whether the function of 
growth factors at altitude extends beyond their currently accepted roles in adaptation. 
Likewise, changes in the growth factor milieu may be an expression of metabolic rather than 
immunological responses to stressors such as hypoxia as well as physical exercise.  
Most exercise studies are conducted in humans and analyze blood samples. In order to grasp the 
extent of both systemic and local changes in growth factors, other types of specimen need to be 
incorporated, as well. Parallel measurements of, for instance, urine, saliva, or cell tissue biopsies 
might contribute greatly to the current knowledge of growth factor environment and network. 
It has to be acknowledged that measurements at given times always can only reflect a growth factor 
concentration at that point in time. Furthermore, the lack of methods of constant sensing and 
measuring of growth factor concentrations aggravates the understanding of interactions of growth 
factors among one another and with other tissues.  
Besides in vitro studies, in vivo studies are required in humans because they possess the advantage 
of the applicability to human pathologies.   
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The dynamic response of growth factors to acute physical stress by exercise appears to be complex 
and does not follow linear courses of time. This has to be borne in mind when evaluating 
investigations of exercise training-induced responses in growth factors. There are studies like the one 
of Schobersberger et al., who measured constantly elevated levels of VEGF at time intervals of 5 
minutes, 2 hours, 24 hours, 2 days, and 5 days after exercise [130]. In contrast, the present study 
showed no significant changes 3 hours after exercise which indicates that any potential changes in 
growth factor concentrations are not sustained at 3 hours after cessation of exercise.   
Whether or not growth factor concentrations were similarly reduced or elevated earlier during or 
after exercise remains to be investigated by future studies.  
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7. Appendix 
Table 7 shows the expedition itinerary with starting and end points and corresponding altitudes of each expedition 
day.  
Table 7 Expedition itinerary 
The expedition itinerary is outlined by showing starting and end points of each expedition day with corresponding 
altitudes.  
BC Base Camp, m meters 
Day From To Altitude (m) Comments  Start End Difference  
1. Beni Babichar 826 970 144   
2. Babichar Phedi 970 1007 37   
3. Phedi Muna 1007 1701 694   
4. Muna Jugapani 1701 1433 268   
5. Jugapani Bogara 1433 2110 677   
6. Bogara Bogara 2110 2110 0 Rest day 
7. Bogara Dobang 2110 2475 365   
8. Dobang Dobang 2475 2475 0 Rest day 
9. Dobang Salagari 2475 3000 525   
10. Salagari Italian BC 3000 3606 606   
11. Italian BC Italian BC 3606 3606 0 Rest day 
12. Italian BC Japanese BC 3606 4220 614   
13. Japanese BC Dhaulagiri BC 4220 4691 471   
14. Dhaulagiri BC Hidden Valley BC 4691 5050 359   
15. Hidden Valley BC Hidden Valley BC 5050 5050 0 Research 
16. Hidden Valley BC Hidden Valley BC 5050 5050 0 Research 
17. Hidden Valley BC Hidden Valley BC 5050 5050 0 Research 
18. Hidden Valley BC Hidden Valley BC 5050 5050 0 Research 
19. Hidden Valley BC Hidden Valley BC 5050 5050 0 Research 
20. Hidden Valley BC Hidden Valley BC 5050 5050 0 Research 
21. Hidden Valley BC Yak Kharka 5050 3885 1165   
22. Yak Kharka Marpha 3885 2670 1215   
23. Marpha Jomson 2670 2720 50    
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Figures 10 and 11 show the well map according to the manufacturer’s user guide.  
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Figure 10 Well map 
The well map for growth factor analysis via Luminex according to the manufacturer’s user guide. 96 wells are filled 
with standard, serial dilutions of standard, quality controls, and samples.  [118] 
QC quality control, pg pictogram, ml milliliter 
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Figure 11 Well map TGF-β1 
The well map for TGF-β1 analysis via Luminex according to the manufacturer’s user guide. 96 wells are filled with 
standard, serial dilutions of standard, quality controls, and samples. [184] 
QC quality control, pg pictogram, ml milliliter 
 
Following graphs show significant growth factor changes in resting subjects at sea level (69 m) and 
high altitude (5050 m).   
Hematological growth factors G-CSF (p = 0.029) and GM-CSF (p = 0.035) showed a significant rise at 
high altitude (5050 m) (see figures 12 and 13). 
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Figure 12 G-CSF at rest 
G-CSF levels increased significantly (p = 0.029) in resting subjects when levels at sea level (69 m) 35.5 (14.8; 77.2) 
were compared to levels at high altitude (5050 m) 50.3 (21.9; 161.3) [pg/ml, Median (Min; Max) rounded values]. 
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Figure 13 GM-CSF at rest 
GM-CSF levels increased significantly (p = 0.035) in resting subjects when levels at sea level (69 m) 3.2 (1.9; 50.0) 
were compared to levels at high altitude (5050 m) 4.0 (1.9; 48.8) [pg/ml, Median (Min; Max) rounded values]. 
 
Significant increases of the vascular growth factors were shown in EGF (p = 0.002), VEGF (p = 0.039), 
and TGF-β1 (p < 0.001) at high altitude (5050 m) (see figures 14 through 16). 
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Figure 14 EGF at rest 
EGF levels increased significantly (p = 0.002) in resting subjects when levels at sea level (69 m) 5.8 (2.9; 138.5) 
were compared to levels at high altitude (5050 m) 10.7 (3.2; 2047.2) [pg/ml, Median (Min; Max) rounded values]. 
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Figure 15 VEGF at rest 
VEGF levels increased significantly (p = 0.039) in resting subjects when levels at sea level (69 m) 160.5 (11.4; 
616.1) were compared to levels at high altitude (5050 m) 362.5 (11.4; 1520.2) [pg/ml, Median (Min; Max) rounded 
values].  
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Figure 16 TGF-β1 at rest 
TGF-β1 levels increased significantly (p < 0.001) in resting subjects when levels at sea level (69 m) 2566.8 (310.8; 
9265.2) were compared to levels at high altitude (5050 m) 17116.5 (294.0; 75043.2) [pg/ml, Median (Min; Max) 
rounded values].  
 
Of the insulin axis, IGF-1 (p < 0.001) and IGFBP-3 (p < 0.001) showed a significant decrease at high 
altitude (5050 m) when compared to sea level values (see figures 17 and 18). 
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Figure 17 IGF-1 at rest 
IGF-1 levels decreased significantly (p < 0.001) in resting subjects when levels at sea level (69 m) 167 (96.3; 360) 
were compared to levels at high altitude (5050 m) 130 (71.8; 212) [µg/l, Median (Min; Max) rounded values]. 
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Figure 18 IGFBP-3 at rest 
IGFBP-3 levels decreased significantly (p < 0.001) in resting subjects when levels at sea level (69 m) 2.6 (1.6; 4.2) 
were compared to levels at high altitude (5050 m) 2.1 (0.8; 3.6) [mg/l, Median (Min; Max) rounded values]. 
 
Apart from growth factors, also differential blood counts showed some significant changes. 
Lymphocytes (p = 0.048) were significantly decreased and neutrophil counts (p = 0.022) were 
significantly increased at high altitude (5050 m) (see figures 19 and 20). 
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Figure 19 Lymphocytes at rest 
Lymphocyte levels decreased significantly (p = 0.048) in resting subjects when levels at sea level (69 m) 51.0 (20.0; 
72.0) were compared to levels at high altitude (5050 m) 39.0 (16.0; 64.0) [%, Median (Min; Max) rounded values].  
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Figure 20 Neutrophils at rest 
Neutrophil levels increased significantly (p = 0.022) in resting subjects when levels at sea level (69 m) 45.0 (23.0; 
73.0) were compared to levels at high altitude (5050 m) 56.0 (36.0; 81.0) [%, Median (Min; Max) rounded values].  
 
While partial oxygen pressure (p < 0.001) and oxygen saturation (p < 0.001) were significantly 
decreased at high altitude (5050 m), hemoglobin levels were significantly increased (p < 0.001) (see 
figures 21 through 23). 
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Figure 21 pO2 at rest 
pO2 decreased significantly (p < 0.001) in resting subjects when levels at sea level (69 m) 760.0 (760.0; 760.0) were 
compared to levels at high altitude (5050 m) 554.0 (554.0; 555.0) [mmHg, Median (Min; Max) rounded values].  
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Figure 22 O2 saturation at rest 
O2 saturation decreased significantly (p < 0.001) in resting subjects when levels at sea level (69 m) 96.0 (74.5; 98.5) 
were compared to levels at high altitude (5050 m) 80.0 (61.0; 96.0) [%, Median (Min; Max) rounded values].  
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Figure 23 Hemoglobin at rest 
Hemoglobin increased significantly (p < 0.001) in resting subjects when levels at sea level (69 m) 140.0 (95.0; 
169.0) were compared to levels at high altitude (5050 m) 159.5 (120.0; 196.0) [g/l, Median (Min; Max) rounded 
values].  
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